var title_f36_48_37632="Gentamicin: Pediatric drug information";
var content_f36_48_37632=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gentamicin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/36/37443?source=see_link\">",
"       Gentamicin (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/63/8185?source=see_link\">",
"       Gentamicin (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/20/31042?source=see_link\">",
"       Gentamicin (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13332 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37632=[""].join("\n");
var outline_f36_48_37632=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/36/37443?source=related_link\">",
"      Gentamicin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/63/8185?source=related_link\">",
"      Gentamicin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/20/31042?source=related_link\">",
"      Gentamicin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_48_37633="Gastric erosion after gastric banding - Case 2";
var content_f36_48_37633=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Case 2: Gastric erosion after gastric banding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast on esophagram empties around the band and not through the central channel in this partially intragastric eroded band.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37633=[""].join("\n");
var outline_f36_48_37633=null;
var title_f36_48_37634="Sodium fluoride F18: Patient drug information";
var content_f36_48_37634=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium fluoride F18: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/52/4931?source=see_link\">",
"     see \"Sodium fluoride F18: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15405179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560724",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with an imaging test of the bones.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15404816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4004982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium fluoride F18 or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15404819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15404820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15404818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694819",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids after the test is over unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4004985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Empty your bladder often for the first 12 hours after the test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15404821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87031 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37634=[""].join("\n");
var outline_f36_48_37634=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15405179\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404816\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404819\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404820\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404818\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404821\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/52/4931?source=related_link\">",
"      Sodium fluoride F18: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_48_37635="Osteonecrosis hip STIR MRI";
var content_f36_48_37635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Avascular necrosis (AVN)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal STIR image of the pelvis shows a low signal intensity lesion of the left femoral head with surrounding bone marrow edema consistent with avascular necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37635=[""].join("\n");
var outline_f36_48_37635=null;
var title_f36_48_37636="Calcitonin: Patient drug information";
var content_f36_48_37636=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Calcitonin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     see \"Calcitonin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/55/15220?source=see_link\">",
"     see \"Calcitonin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fortical&reg;;",
"     </li>",
"     <li>",
"      Miacalcin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F144122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Calcitonin&reg;;",
"     </li>",
"     <li>",
"      Calcimar&reg;;",
"     </li>",
"     <li>",
"      Caltine&reg;;",
"     </li>",
"     <li>",
"      Miacalcin&reg; NS;",
"     </li>",
"     <li>",
"      PRO-Calcitonin;",
"     </li>",
"     <li>",
"      Sandoz-Calcitonin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat soft, brittle bones (osteoporosis) in women after change of life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Paget's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691890",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high calcium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701682",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to calcitonin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702902",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to salmon.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nose spray:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the nose only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change nostrils every day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin or a muscle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699569",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened nose spray bottle in a refrigerator until ready to use. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699517",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store opened nose spray bottle upright at room temperature. Throw away any part not used after 30 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11631 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37636=[""].join("\n");
var outline_f36_48_37636=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144121\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144122\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030710\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030709\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030714\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030715\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030717\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030712\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030713\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030718\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030719\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=related_link\">",
"      Calcitonin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/55/15220?source=related_link\">",
"      Calcitonin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_48_37637="Bullous pemphigoid on urticarial plaque PI";
var content_f36_48_37637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows blisters on red, raised areas of skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37637=[""].join("\n");
var outline_f36_48_37637=null;
var title_f36_48_37638="Epidemiology and pathogenesis of candidemia in adults";
var content_f36_48_37638=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of candidemia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/48/37638/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/48/37638/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/48/37638/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/48/37638/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/48/37638/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/48/37638/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/48/37638/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term candidemia describes the presence of Candida species in the blood. Candida in a blood culture should never be viewed as a contaminant and should always prompt a search for the source of infection. For many patients, candidemia is a manifestation of disseminated candidiasis, whereas for others it reflects colonization of an indwelling intravenous catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical issues related to the epidemiology and pathogenesis of candidemia will be reviewed here. The clinical manifestations, diagnosis, and treatment of candidemia, as well as an overview of Candida infections are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36966?source=see_link\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidiasis is an increasingly important nosocomial infection in both adults and children, especially those who are cared for in intensive care units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/2-8\">",
"     2-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36406?source=see_link\">",
"     \"Epidemiology and pathogenesis of and risk factors for surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the infecting strain is most often part of the host's endogenous flora, nosocomial acquisition of Candida species has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The organism has spread via contaminated solutions in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/8\">",
"     8",
"    </a>",
"    ], whereas the hands of healthcare workers were the probable source in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence of Candida species",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although C. albicans is the most common cause of candidemia, there has been increased isolation of non-albicans species of Candida in recent years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/11-20\">",
"     11-20",
"    </a>",
"    ]. In a multicenter surveillance study conducted in the United States between 2004 and 2008, 54 percent of 2019 bloodstream isolates represented non-albicans Candida spp and 46 percent represented C. albicans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/18\">",
"     18",
"    </a>",
"    ]. C. glabrata was responsible for 26 percent of all cases of candidemia, followed by C. parapsilosis (16 percent), C. tropicalis (8 percent), and C. krusei (3 percent). Other studies have shown a similar order of frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], although the incidence of each species varies in different patient populations and geographic regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/21\">",
"     21",
"    </a>",
"    ]. As an example, in Latin America, the most common species to cause bloodstream infection after C. albicans are C. parapsilosis and C. tropicalis, with C. glabrata being isolated much less frequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Knowing the prevalence of the non-albicans Candida species is important because susceptibility to antifungal agents varies among the species. As an example, all isolates of C. krusei are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    resistant and a variable proportion of C. glabrata are fluconazole resistant. Risk factors for candidemia caused by fluconazole-resistant isolates, mostly C. glabrata, include neutropenia, chronic renal disease, chronic lung disease, male gender, and previous fluconazole or other antifungal exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Additionally, resistance to fluconazole has been found in a small proportion of isolates of C. albicans, C. parapsilosis, and C. tropicalis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Susceptibility patterns'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'C. glabrata and C. krusei'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is postulated that the trend toward increasing isolation of non-albicans Candida species is related to the selective pressure associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/13,25,26\">",
"     13,25,26",
"    </a>",
"    ], and some studies provide strong evidence for this association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/25,27,28\">",
"     25,27,28",
"    </a>",
"    ]. In addition to azole use, there are other factors, such as echinocandin use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/28\">",
"     28",
"    </a>",
"    ], geography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/27\">",
"     27",
"    </a>",
"    ], age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/29\">",
"     29",
"    </a>",
"    ], and perhaps other issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/30\">",
"     30",
"    </a>",
"    ], that contribute to these trends. The prevalence of and risk factors for infection with non-albicans Candida species in specific populations are discussed below. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Patients in intensive care'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6\">",
"     'Immunocompromised patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in the intensive care unit (ICU) and those who are immunocompromised are most at risk for the development of candidemia. Risk factors for nosocomial candidemia were evaluated in a case-control study of 113 patients with candidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/31\">",
"     31",
"    </a>",
"    ]. Five significant predictors of candidemia were identified on multivariate analysis: Hickman catheters (adjusted odds ratio [OR] 9.5), gastric acid suppressants (adjusted OR 6.4), ICU admission (adjusted OR 6.4), nasogastric tube (adjusted OR 3.7), and the administration of antibiotics (adjusted OR 1.5 per antibiotic given).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Patients in intensive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in ICUs account for the greatest number of episodes of candidemia in most hospitals. Surgical units, especially those caring for trauma and burn patients, and neonatal units have the highest rates of Candida infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/9\">",
"     9",
"    </a>",
"    ]. Besides the risks associated with the extremes of age and trauma or burns, other factors include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/3,11,32\">",
"     3,11,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Central venous catheters",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"       Total parenteral nutrition",
"      </a>",
"     </li>",
"     <li>",
"      Broad-spectrum antibiotics",
"     </li>",
"     <li>",
"      High APACHE scores",
"     </li>",
"     <li>",
"      Acute renal failure, particularly if requiring hemodialysis",
"     </li>",
"     <li>",
"      Prior surgery, particularly abdominal surgery",
"     </li>",
"     <li>",
"      Gastrointestinal tract perforations and anastomotic leaks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a prospective multicenter study of 300 ICU patients in France with proven invasive candidiasis, C. albicans was the most common species isolated (57 percent), followed by C. glabrata (17 percent), C. parapsilosis (8 percent), C. krusei (5 percent), and C. tropicalis (5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Susceptibility patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for candidemia with non-albicans Candida species were assessed in a retrospective case-comparator study of patients with candidemia (non-albicans Candida compared to C. albicans) in the medical and surgical ICUs of two tertiary care hospitals in the United States from 1995 to 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/33\">",
"     33",
"    </a>",
"    ]. Two significant risk factors for candidemia with non-albicans species were identified on multivariate analysis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      exposure (OR 11.6, 95% CI 2.3 to 58.9)",
"     </li>",
"     <li>",
"      Central venous catheter exposure (OR 2.0, 95% CI 1.1 to 3.5)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent prospective cohort study that included 179 episodes of ICU-acquired candidemia showed that prior gastrointestinal surgery and systemic antifungal exposure were independently significant variables that were associated with bloodstream infection with both non-albicans Candida species and potentially",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    -resistant Candida species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another prospective cohort study that included 154 cases of ICU-acquired candidemia in non-neutropenic patients, independent risk factors for C. glabrata infection included age &gt;60 years, recent abdominal surgery, interval from ICU admission to first positive blood culture &le;7 days, recent cephalosporin use, solid tumor, and absence of diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings may help determine initial empiric therapy for candidemia since patients with non-albicans Candida infection are more likely to have a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    -resistant isolate than those with C. albicans infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Susceptibility patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Immunocompromised patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised patients are at special risk for candidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/11-13,35-37\">",
"     11-13,35-37",
"    </a>",
"    ]. High-risk groups include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Those with hematologic malignancies",
"     </li>",
"     <li>",
"      Recipients of solid organ or hematopoietic stem cell transplants",
"     </li>",
"     <li>",
"      Those given chemotherapeutic agents, especially those associated with extensive gastrointestinal mucosal damage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neutropenia is common in these settings, and most transplant recipients are also receiving glucocorticoids. Other risk factors include broad-spectrum antibiotics and central venous catheters.",
"   </p>",
"   <p>",
"    The proportion of Candida infections caused by non-albicans Candida has been rising dramatically at some medical centers in patients with hematological malignancies compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/21,37,38\">",
"     21,37,38",
"    </a>",
"    ]. In a retrospective study of 635 patients with candidemia at a cancer center from 1993 to 2003, C. glabrata and C. krusei were the most common causes of candidemia, accounting for 31 and 24 percent of episodes in patients with hematologic malignancy. However, in solid organ transplant recipients, only 18 and 2 percent were caused by these species, respectively. On multivariate analysis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis was a risk factor for both C. glabrata and C. krusei candidemia, neutropenia was a risk factor for all candidemias, and central venous catheter-related infection was a risk factor for C. parapsilosis candidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings have important implications for the empiric treatment of candidemia in patients with hematological malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'C. glabrata and C. krusei'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H230581572#H230581572\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Empiric antifungal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major routes by which Candida gain access to the bloodstream:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Through the gastrointestinal tract mucosal barrier",
"     </li>",
"     <li>",
"      Via an intravascular catheter",
"     </li>",
"     <li>",
"      From a localized focus of infection, such as pyelonephritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetration through the gastrointestinal tract mucosa is probably the most common mechanism for Candida species to enter the bloodstream in both neutropenic patients and in ICU patients. Candida species are part of the normal bowel flora; many of the factors noted above lead to overgrowth of yeasts and subsequent egress out of the bowel into the blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intravascular catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloodstream infection associated with intravascular catheters has become increasingly important. Candida colonization of indwelling vascular devices, especially central catheters, can occur at either the insertion site or the hub and lead to subsequent candidemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     Total parenteral nutrition",
"    </a>",
"    (TPN) is an important risk factor for candidemia. Although the mechanism by which TPN increases the risk of candidemia is not well understood, one in vitro study suggested that the lipid emulsion present in TPN solutions increases biofilm production on silicone-elastomer catheters, and supports growth of C. albicans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Localized focus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloodstream invasion is relatively uncommon from a localized focus of infection but has been well described with ascending Candida urinary tract infection associated with either intrinsic obstruction (eg, from a fungus ball) or extrinsic compression preventing the flow of infected urine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15128?source=see_link\">",
"     \"Candida infections of the bladder and kidneys\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonization with Candida species is an independent predictor of candidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37638/abstract/40\">",
"     40",
"    </a>",
"    ]. Although colonization alone does not predict which patients will develop fungemia, candidemia is very uncommon in a patient who is free of colonizing yeasts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candida in a blood culture should never be viewed as a contaminant and should always prompt a search for the source of the fungemia. For many patients, candidemia is a manifestation of disseminated candidiasis, whereas for others it reflects colonization of an indwelling intravenous catheter. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Candidiasis is an increasingly important nosocomial infection in both adults and children, especially those who are cared for in intensive care units (ICUs). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the infecting strain is most often part of the host's endogenous flora, nosocomial acquisition of Candida species has been described. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There has been increased isolation of non-albicans species of Candida from bloodstream infections. Most prominent have been C. glabrata and C. parapsilosis, followed by C. tropicalis, and C. krusei. All C. krusei are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant and a variable proportion of C. glabrata are fluconazole-resistant. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence of Candida species'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients in the ICU and those who are immunocompromised (eg, patients with hematologic malignancies, solid organ and hematopoietic stem cell transplant recipients) are most at risk for the development of candidemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three major routes by which Candida gain access to the bloodstream: through the gastrointestinal tract mucosal barrier, via an intravascular catheter, and from a localized focus of infection, such as pyelonephritis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Penetration through the gastrointestinal tract mucosa is probably the most common mechanism for Candida species to enter the bloodstream in both immunocompromised patients (eg, those receiving chemotherapy who are neutropenic) and in ICU patients. Candida species are part of the normal bowel flora; many factors lead to overgrowth of yeasts and subsequent egress out of the bowel into the blood. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gastrointestinal tract'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bloodstream infection associated with intravascular catheters has become increasingly important. Candida colonization of indwelling vascular devices, especially central catheters, can occur at either the insertion site or the hub and lead to subsequent candidemia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Intravascular catheters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colonization with Candida species is an independent predictor of candidemia. Although colonization alone does not predict which patients will develop fungemia, candidemia is very uncommon in a patient who is free of colonizing yeasts. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Colonization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/1\">",
"      Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/2\">",
"      Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/3\">",
"      Chow JK, Golan Y, Ruthazer R, et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008; 36:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/4\">",
"      Playford EG, Marriott D, Nguyen Q, et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008; 36:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/5\">",
"      Playford EG, Nimmo GR, Tilse M, Sorrell TC. Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999-2008. J Hosp Infect 2010; 76:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/6\">",
"      Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/7\">",
"      Arendrup MC, Fuursted K, Gahrn-Hansen B, et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008; 14:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/8\">",
"      Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/9\">",
"      Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/10\">",
"      Vazquez JA, Sanchez V, Dmuchowski C, et al. Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis 1993; 168:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/11\">",
"      Nucci M, Colombo AL, Silveira F, et al. Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 1998; 19:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/12\">",
"      Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/13\">",
"      Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/14\">",
"      Malani A, Hmoud J, Chiu L, et al. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005; 41:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/15\">",
"      Almirante B, Rodr&iacute;guez D, Cuenca-Estrella M, et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006; 44:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/16\">",
"      Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 2006; 44:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/17\">",
"      Trofa D, G&aacute;cser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008; 21:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/18\">",
"      Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/19\">",
"      Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/20\">",
"      Lyon GM, Karatela S, Sunay S, et al. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol 2010; 48:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/21\">",
"      Riddell J 4th, Kauffman CA. The evolution of resistant Candida species in cancer centers: implications for treatment and prophylaxis. Cancer 2008; 112:2334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/22\">",
"      Nucci M, Queiroz-Telles F, Tob&oacute;n AM, et al. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 2010; 51:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/23\">",
"      Garnacho-Montero J, D&iacute;az-Mart&iacute;n A, Garc&iacute;a-Cabrera E, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010; 54:3149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/24\">",
"      Oxman DA, Chow JK, Frendl G, et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother 2010; 65:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/25\">",
"      Abbas J, Bodey GP, Hanna HA, et al. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med 2000; 160:2659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/26\">",
"      Malani PN, Bradley SF, Little RS, Kauffman CA. Trends in species causing fungaemia in a tertiary care medical centre over 12 years. Mycoses 2001; 44:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/27\">",
"      Cuenca-Estrella M, Rodriguez D, Almirante B, et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005; 55:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/28\">",
"      Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011; 55:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/29\">",
"      Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/30\">",
"      Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005; 49:4555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/31\">",
"      Puzniak L, Teutsch S, Powderly W, Polish L. Has the epidemiology of nosocomial candidemia changed? Infect Control Hosp Epidemiol 2004; 25:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/32\">",
"      Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/33\">",
"      Chow JK, Golan Y, Ruthazer R, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008; 46:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/34\">",
"      Cohen Y, Karoubi P, Adrie C, et al. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients. Crit Care Med 2010; 38:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/35\">",
"      Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/36\">",
"      Lecciones JA, Lee JW, Navarro EE, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992; 14:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/37\">",
"      Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/38\">",
"      Pfaller MA, Diekema DJ, Rinaldi MG, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43:5848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/39\">",
"      Swindell K, Lattif AA, Chandra J, et al. Parenteral lipid emulsion induces germination of Candida albicans and increases biofilm formation on medical catheter surfaces. J Infect Dis 2009; 200:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37638/abstract/40\">",
"      Verduyn Lunel FM, Meis JF, Voss A. Nosocomial fungal infections: candidemia. Diagn Microbiol Infect Dis 1999; 34:213.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2442 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B64CF0B05F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37638=[""].join("\n");
var outline_f36_48_37638=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence of Candida species",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Patients in intensive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intravascular catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Localized focus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Colonization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15128?source=related_link\">",
"      Candida infections of the bladder and kidneys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36406?source=related_link\">",
"      Epidemiology and pathogenesis of and risk factors for surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_48_37639="Tumor evolution in AML";
var content_f36_48_37639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F84023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F84023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 742px\">",
"   <div class=\"ttl\">",
"    Examples of the two major patterns of tumor evolution in acute myeloid leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 722px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Model 1 shows the dominant clone in the primary tumor evolving into the relapse clone by gaining relapse specific mutations; this pattern was identified in three primary tumor and relapse pairs. Model 2 shows a minor clone carrying the vast majority of the primary tumor mutations survived and expanded at relapse. This pattern was observed in five primary tumor and relapse pairs.",
"    <div class=\"footnotes\">",
"     AML: acute myeloid leukemia; HSCs: hematopoietic stem cells.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Nature 2012; 481:506. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole-genome sequencing. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37639=[""].join("\n");
var outline_f36_48_37639=null;
var title_f36_48_37640="Vasopressin receptor mutations";
var content_f36_48_37640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Mutations in the vasopressin 2 receptor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the vasopressin 2 receptor (AVPR2), showing individual amino acids (one letter code). AVPR2 consists of seven hydrophobic domains and multiple extracellular and intracellular loops. Seventy-two mutations in this receptor, depicted in blue, have been associated with nephrogenic diabetes insipidus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bichet, DG, Oksche, A, Rosenthal, W, J Am Soc Nephrol 1997; 8:1951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37640=[""].join("\n");
var outline_f36_48_37640=null;
var title_f36_48_37641="Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval";
var content_f36_48_37641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/48/37641/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/48/37641/contributors\">",
"     Alfred Buxton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/48/37641/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/48/37641/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/48/37641/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/48/37641/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/48/37641/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphic (or polymorphous) ventricular tachycardia (VT) is defined as an unstable rhythm at a rate greater than 100 beats per minute with a continuously varying QRS complex morphology in any recorded electrocardiographic (ECG) lead (",
"    <a class=\"graphic graphic_waveform graphicRef54538 \" href=\"mobipreview.htm?7/6/7271\">",
"     waveform 1",
"    </a>",
"    ). The simultaneous recording of more than one ECG lead is often necessary to detect these changes. Most polymorphic VTs are rapid (often &gt;200 bpm), but an absolute rate has not been established, and VT at a slower rate can manifest changing QRS morphology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/1\">",
"     1",
"    </a>",
"    ]. Some episodes of polymorphic VT cause hemodynamic collapse, and some degenerate into ventricular fibrillation (VF); however, many episodes terminate spontaneously (",
"    <a class=\"graphic graphic_waveform graphicRef54538 \" href=\"mobipreview.htm?7/6/7271\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Polymorphic VTs are classified based upon their association with a normal or prolonged QT interval. Spontaneous polymorphic VT in the presence of a normal QT interval usually occurs in the setting of coronary heart disease or non-ischemic cardiomyopathy. However, some patients have no structural heart disease and may have a familial syndrome.",
"   </p>",
"   <p>",
"    Polymorphic VT associated with a normal QT interval will be reviewed here. Polymorphic ventricular tachycardia associated with a prolonged QT interval, which has a different etiology and mechanism, is known as torsades de pointes (\"twisting of points\") and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link&amp;anchor=H2#H2\">",
"     \"Acquired long QT syndrome\", section on 'Torsades de pointes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features of congenital long QT syndrome\", section on 'Torsades de pointes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CATECHOLAMINERGIC POLYMORPHIC VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catecholaminergic polymorphic VT (CPVT), also known as familial catecholaminergic polymorphic VT, occurs in the absence of structural heart disease or known associated syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/2-10\">",
"     2-10",
"    </a>",
"    ]. This disorder typically begins in childhood or adolescence, although cases have been reported with initial presentation in the fourth decade of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/5\">",
"     5",
"    </a>",
"    ]. Affected patients may have a family history of juvenile sudden death or stress-induced syncope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. CPVT may also present sporadically as a de novo mutation in individuals with no family history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/5,11\">",
"     5,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients typically present with life-threatening VT or ventricular fibrillation (VF) occurring during emotional or physical stress, with syncope often being the first manifestation of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. Arrhythmic events during swimming, previously considered to be specific for long QT syndrome type 1, have also been described with this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/13\">",
"     13",
"    </a>",
"    ]. The VT morphology may vary continuously, from beat to beat, or may appear as a bidirectional VT that resembles the arrhythmia associated with digitalis toxicity (",
"    <a class=\"graphic graphic_waveform graphicRef71796 \" href=\"mobipreview.htm?28/24/29063\">",
"     waveform 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. Presentation with VF is less common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Digitalis toxicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Multiple mechanisms may be involved, as tendencies have been noted toward sinus bradycardia, U waves, a short PR interval, or arrhythmia induced by sinus tachycardia occurring with exercise, emotion, or catecholamine infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/4,5,9\">",
"     4,5,9",
"    </a>",
"    ]. These various patterns suggest that the mechanism may be reentry and delayed afterdepolarizations due to calcium overload or changes in autonomic tone. Arrhythmia typically cannot be induced at electrophysiologic study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H237249870\">",
"    <span class=\"h2\">",
"     ECG characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG during sinus rhythm is generally normal. Two types of polymorphic tachycardias have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"Typical\" polymorphic VT with continuously varying QRS morphology, similar to that seen in patients with acute ischemia or non-ischemic cardiomyopathies",
"     </li>",
"     <li>",
"      Bidirectional tachycardia demonstrating alternans of the QRS complexes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in two genes have been identified in patients with CPVT: the cardiac ryanodine receptor gene and the calsequestrin 2 gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cardiac ryanodine receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;An autosomal dominant form of CPVT was initially linked to chromosome 1q42-q43 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/6\">",
"     6",
"    </a>",
"    ]. Subsequent studies identified mutations in the gene for the human cardiac ryanodine receptor (RyR2), which is also called the cardiac sarcoplasmic calcium release channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/5,7,8,15,16\">",
"     5,7,8,15,16",
"    </a>",
"    ]. One report suggested that RyR2 mutations may account for at least one in every seven cases of sudden unexplained death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RyR2 mediates the release of calcium from the sarcoplasmic reticulum that is required for myocardial contraction. The FK506 binding protein (FKBP12.6) stabilizes RyR2, preventing aberrant activation. The mutations in RyR2 in familial polymorphic VT interfere with the interaction with FKBP12.6, increasing channel activity under conditions in which RyR2 is activated (eg, simulated exercise, beta adrenergic stimulation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. The \"leaky\" RyR2 channels in these settings increase calcium release and can trigger life-threatening ventricular arrhythmias, possibly via delayed afterdepolarizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/15,18,19\">",
"     15,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of this form of familial polymorphic VT were evaluated in two unrelated families with 24 members who had experienced exercise-induced VT or syncope or had an episode of cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/6\">",
"     6",
"    </a>",
"    ]. Some of the family members had delayed clinical manifestations, which necessitated continued observation and repeated evaluation. The cumulative incidence of sudden cardiac death by the age of 30 was 31 percent. Only one heterozygous carrier was clinically unaffected, suggesting high disease penetrance by adulthood.",
"   </p>",
"   <p>",
"    The frequency with which RyR2 mutations occur in patients with CPVT was assessed in a series of 30 probands and 118 family members [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/5\">",
"     5",
"    </a>",
"    ]. RyR2 mutations were detected in 14 of the 30 probands (47 percent) and in nine family members, four of whom were silent carriers. The patients with RyR2 mutations, compared to those without such mutations, had events at a younger age (age at first syncope 8 versus 20 years), and male sex was an important risk factor for syncope. In contrast, 90 percent of the subjects without an RyR2 mutation were female. The distribution of arrhythmias in these 14 patients was polymorphic VT in 7, bidirectional VT in 5, and catecholaminergic idiopathic ventricular fibrillation in 2.",
"   </p>",
"   <p>",
"    Two other types of RyR2 mutations differ from those associated with familial polymorphic VT in structurally normal hearts. A large genomic deletion in RyR2 that leads to polymorphic VT and extended phenotypes (including sinoatrial node and atrioventricular node dysfunction, atrial fibrillation, atrial standstill and dilated LV cardiomyopathy) has been identified in 16 members of two separate families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/20\">",
"     20",
"    </a>",
"    ]. Another mutation in RyR2 is responsible for exercise-induced familial polymorphic VT occurring in arrhythmogenic right ventricular cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23528?source=see_link\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Calsequestrin 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second genetic form of CPVT, with autosomal recessive inheritance, involves the calsequestrin 2 gene (CASQ2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/9,24,25\">",
"     9,24,25",
"    </a>",
"    ]. This form was first identified in seven related Bedouin families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/9\">",
"     9",
"    </a>",
"    ]. These families included nine children who died suddenly at an average age of 7 years and 12 others with a history of recurrent syncope or seizures beginning at 6 years of age. The 12 symptomatic patients had a relative resting bradycardia and polymorphic VT induced by exercise or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    infusion.",
"   </p>",
"   <p>",
"    The calsequestrin 2 protein, which serves as the major calcium reservoir within the sarcoplasmic reticulum of cardiac myocytes, has an ability to bind extremely large amounts of calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/26\">",
"     26",
"    </a>",
"    ]. While the mechanism by which the reported mutation causes ventricular arrhythmias is not clearly established, the mutated protein may alter the calcium content within the sarcoplasmic reticulum, alter the function of the ryanodine receptor to which it is connected, or impair the calcium release process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/24,25,27\">",
"     24,25,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10798824\">",
"    <span class=\"h2\">",
"     Acute management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for the management of ventricular arrhythmias and the prevention of sudden cardiac death included recommendations for the management of polymorphic VT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/28\">",
"     28",
"    </a>",
"    ]. Because acute management decisions are often made in the absence of a detailed knowledge of underlying cardiac disease, the recommendations do not make clear distinctions based upon the presence of CHD or familial disease.",
"   </p>",
"   <p>",
"    The author and reviewers of this topic agree with the suggested acute treatment of polymorphic VT as provided in the",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines and summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If hemodynamic compromise is present, immediate direct current cardioversion should be performed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6473?source=see_link&amp;anchor=H15#H15\">",
"       \"Overview of the acute management of tachyarrhythmias\", section on 'Hemodynamically unstable arrhythmia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For recurrent polymorphic VT, intravenous beta blockers should be administered, especially if ischemia is suspected or cannot be excluded [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/3,5\">",
"       3,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For recurrent polymorphic VT in the absence of congenital or acquired QT interval prolongation, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      should be administered. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6473?source=see_link&amp;anchor=H16#H16\">",
"       \"Overview of the acute management of tachyarrhythmias\", section on 'Polymorphic ventricular tachycardia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urgent coronary angiography should be performed if ongoing myocardial ischemia cannot be excluded. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link&amp;anchor=H23#H23\">",
"       \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Immediate angiography and revascularization'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chronic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with CPVT who have sustained ventricular arrhythmias are treated with an implantable cardioverter-defibrillator (ICD) to terminate arrhythmias and prevent syncope",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sudden cardiac death. However, patients should also receive medical therapy in addition to the ICD in an effort to prevent arrhythmias and minimize ICD shocks. Given the catecholaminergic nature of the arrhythmias, it is not surprising that beta blockers form the cornerstone of treatment. The reported results of beta blocker therapy have been variable, however, which may in part reflect differences in the underlying genetic mutation. In patients with ongoing arrhythmias despite therapy with a beta blocker, the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    may be effective for suppressing ventricular arrhythmias.",
"   </p>",
"   <p>",
"    For patients with CPVT, our approach to treatment includes an ICD and beta blockers for most patients, the avoidance of competitive sports, and the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    in patients with ongoing ventricular arrhythmias despite initial therapy. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6470945\">",
"    <span class=\"h3\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to the chronic management of patients with CPVT is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend avoiding competitive sports (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1021006\">",
"       'Avoidance of competitive sports'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We recommend the use of beta blockers for all adult patients with spontaneous or documented stress-induced ventricular arrhythmias (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Beta blockers'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For survivors of cardiac arrest or for patients with syncope or sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) despite therapy with beta blockers, we recommend placement of an implantable cardioverter-defibrillator (ICD) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6471335\">",
"       'Implantable cardioverter-defibrillators'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients taking a beta blocker who have received an ICD and who continue to have stress-induced ventricular arrhythmias, we suggest the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      for further arrhythmia suppression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      may also be considered in patients who are unable to take flecainide due to coronary heart disease or intolerance. The use of all three drugs may be necessary in patients who continue to have ventricular arrhythmias on two drugs. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Flecainide'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H3491591\">",
"       'Calcium channel blockers'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We suggest left sympathetic denervation for patients with CPVT who remain symptomatic after maximal medical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest the use of beta blockers in patients without clinical manifestations who are diagnosed in childhood based upon genetic analysis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Beta blockers'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1021006\">",
"    <span class=\"h3\">",
"     Avoidance of competitive sports",
"    </span>",
"    &nbsp;&mdash;&nbsp;Participation in competitive athletics increases the risk of ventricular arrhythmias in patients with CPVT due to the rise in catecholamines associated with exertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/28\">",
"     28",
"    </a>",
"    ]. As such, we recommend that patients with CPVT avoid competitive sports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the largest reported series, 101 patients with CPVT were followed for a mean of 7.9 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/12\">",
"     12",
"    </a>",
"    ]. Beta blockers were administered to 81 patients (80 percent) immediately after diagnosis. Of those taking a beta blocker, 62 (77 percent) experienced no events during follow-up, and nine (11 percent) experienced fatal or near-fatal events. At least four of these nine patients did not take their beta blocker on the day of the event. The estimated four- and eight-year fatal or near-fatal event rates were 1 and 11 percent, respectively, in the patients on beta blocker therapy, and 18 and 25 percent, respectively, in those not prescribed beta blockers.",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis of 11 observational studies including 403 patients with CPVT revealed that 88 percent of patients were prescribed a beta blocker at some point [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/29\">",
"     29",
"    </a>",
"    ]. No control groups were provided for comparison, so the relative efficacy of beta blockers was not reported. However, the event rates at four and eight years were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arrhythmic events (syncope, aborted cardiac arrest, sudden cardiac death) &ndash; 18.6 and 37.2 percent at four and eight years, respectively",
"     </li>",
"     <li>",
"      Near fatal events (aborted cardiac arrest, sudden cardiac death) &ndash; 7.7 and 15.3 percent",
"     </li>",
"     <li>",
"      Fatal events (sudden cardiac death) &ndash; 3.2 and 6.4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some families, beta blocker therapy completely prevents recurrent arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/4,9\">",
"     4,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3491591\">",
"    <span class=\"h3\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite therapy with beta blockers, some patients continue to have symptomatic arrhythmias associated with CPVT. The addition of a calcium channel blocker, specifically",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , appears to provide some additional benefit in patients with ongoing symptomatic arrhythmias.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of six patients with CPVT treated with beta blockers who were undergoing exercise testing,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      infusion (0.2",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      during the stress test significantly reduced the number of ventricular premature beats compared with exercise testing on beta blockers therapy alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of six patients with ongoing exercise-induced ventricular arrhythmias despite therapy with a beta blocker, the addition of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      led to a reduction in ventricular tachycardia and ectopic ventricular beats [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 11 patients with CPVT who were homozygous for calsequestrin 2 mutation who remained symptomatic despite treatment with beta blockers, the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      decreased the amount of ventricular arrhythmias and increased exercise tolerance during exercise testing in 5 of 11 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While additional investigation is needed to confirm these results in larger numbers of patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    might be considered as an adjunctive therapy for CPVT patients with ongoing ventricular arrhythmias despite beta blockers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Flecainide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    is best known as a blocker of cardiac sodium channels. However, it also inhibits the cardiac ryanodine receptor channel (RyR2). This combined effect makes it an attractive potential therapy for CPVT. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Cardiac ryanodine receptor'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following discussion reviews the evidence supporting the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    in CPVT. When flecainide might be used clinically is discussed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a study that evaluated the molecular mechanisms of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    in animal models, the following findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"       Flecainide",
"      </a>",
"      potently blocked isolated single RyR2 channels. This effect was probably responsible for the ability of flecainide to inhibit the spontaneous release of calcium from the sarcoplasmic reticulum of ventricular myocytes isolated from a calsequestrin \"knock-out\" mouse model of CPVT. Spontaneous calcium release can lead to delayed afterdepolarizations and VT.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"       Flecainide",
"      </a>",
"      suppressed the development of catecholamine-induced polymorphic VT in all 12 calsequestrin \"knock-out\" mice tested. In comparison,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      , a sodium channel blocker that does not inhibit RyR2 channels, suppressed ventricular extrasystoles but not exercise-induced VT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    (median daily dose 150 mg) was assessed in a cohort study of 29 patients with exercise-induced ventricular arrhythmias that persisted despite therapy with a beta blocker or calcium channel blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/34\">",
"     34",
"    </a>",
"    ]. Exercise-induced ventricular arrhythmias were either completely (14 patients) or partially (8 patients) suppressed (76 percent success rate). During a median follow up of 20 months, there were no deaths, and only one patient had a sustained ventricular arrhythmia requiring ICD therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    may also be effective in patients with persistent episodes of CPVT despite therapy with both a beta blocker and a calcium channel blocker. In a report of two such patients, the addition of flecainide prevented further episodes of CPVT, an effect that persisted in one patient after withdrawal of the beta blocker and calcium channel blocker (",
"    <a class=\"graphic graphic_figure graphicRef50360 \" href=\"mobipreview.htm?33/22/34154\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6471335\">",
"    <span class=\"h3\">",
"     Implantable cardioverter-defibrillators",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with most survivors of sudden cardiac death (SCD) from ventricular arrhythmias of other etiologies, patients with CPVT who have survived SCD due to sustained VT or ventricular fibrillation (VF) should receive an implantable cardioverter-defibrillator (ICD) in addition to beta-blocker therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link&amp;anchor=H19#H19\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Our approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with CPVT who develop sustained VT or syncope (for which causes other than VT are excluded) while taking a beta blocker are likely to be at higher risk of future SCD. Electrophysiological testing is generally not helpful in patients with CPVT since the arrhythmia is usually not inducible with programmed ventricular stimulation. In such patients, ICD placement is a reasonable approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/28,36\">",
"     28,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consideration of ICD placement in patients with CPVT should not be undertaken without considerable discussion with patients and their families. ICD shocks may have harmful effects in patients with CPVT, triggering VT storm, in addition to negatively impacting quality of life. In addition, because of the young age of many patients with CPVT, ICD recipients are at long-term risk for complications and repeated procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Sympathetic denervation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from small case series suggest a potential role for left sympathetic denervation in patients with CPVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/11,37,38\">",
"     11,37,38",
"    </a>",
"    ]. The first demonstration of the long-term efficacy of this procedure was in three young adults with RyR2 mutations and inadequate symptom control on beta blockers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/11\">",
"     11",
"    </a>",
"    ]. All three patients exhibited a marked reduction in arrhythmic burden following the procedure. In the largest reported series of 14 patients with CPVT treated with left sympathetic denervation, long-term success was reported in 13 patients (93 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest left sympathetic denervation for patients with CPVT who remain symptomatic after maximal medical therapy. The rationale for and description of left cardiac sympathetic denervation are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26682?source=see_link&amp;anchor=H17#H17\">",
"     \"Prognosis and management of congenital long QT syndrome\", section on 'Left cardiac sympathetic denervation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines for management of patients with ventricular arrhythmias included recommendations regarding the acute management of polymorphic VT. (See",
"    <a class=\"local\" href=\"#H10798824\">",
"     'Acute management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines also included the following specific recommendations for patients with CPVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      general agreement supporting the use of beta blockers for patients clinically diagnosed on the basis of spontaneous or documented stress-induced ventricular arrhythmias.",
"     </li>",
"     <li>",
"      There is evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      general agreement supporting the use of an ICD in combination with beta blockers for survivors of cardiac arrest who have a reasonable expectation of survival with a good functional capacity for more than one year.",
"     </li>",
"     <li>",
"      The weight of evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      opinion supports the use of beta blockers in patients without clinical manifestations who are diagnosed in childhood based upon genetic analysis.",
"     </li>",
"     <li>",
"      The weight of evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      opinion supports the use of an ICD in combination with beta blockers for patients with a history of syncope",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sustained VT while receiving beta blockers who have a reasonable expectation of survival with a good functional capacity for more than one year.",
"     </li>",
"     <li>",
"      The usefulness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      efficacy of beta blockers is less well established in patients without clinical evidence of arrhythmias who are diagnosed in adulthood based upon genetic analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines for device-based therapy of cardiac rhythm abnormalities also included recommendations for the use of ICD therapy in patients with CPVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/35\">",
"     35",
"    </a>",
"    ]. These recommendations are in agreement with those of the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines for management of patients with ventricular arrhythmias and the 2010 Heart Rhythm UK position statement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/28,36\">",
"     28,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SPORADIC POLYMORPHIC VT IN THE STRUCTURALLY NORMAL HEART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphic VT may present in patients with no significant structural heart disease and no family history who do not have catecholaminergic polymorphic VT. One study evaluated 15 such patients who presented with syncope, presyncope, or cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/40\">",
"     40",
"    </a>",
"    ]. The arrhythmia was induced by exercise in four and by coronary vasospasm in two.",
"   </p>",
"   <p>",
"    Electrophysiologic similarities may exist between rapid polymorphic VT in the normal heart and idiopathic ventricular fibrillation (VF). As an example, idiopathic VF is often initiated by a ventricular premature beat with a very short coupling interval; polymorphic VT may also be preceded by a short-long-short cardiac cycle. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15559?source=see_link&amp;anchor=H11#H11\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Idiopathic VF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to making this diagnosis, cardiac catheterization with coronary angiography is necessary to exclude the presence of obstructive coronary artery disease. Some individuals with sporadic disease have undergone genetic testing; some but not all of these patients have de novo mutations similar to mutations observed in patients with familial disease and have therefore been classified as having CPVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/5,11,41\">",
"     5,11,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chronic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are presently no consensus treatment guidelines for the management of sporadic polymorphic VT in an otherwise normal heart. Therapy may be directed by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic beta blocker administration may be effective in some patients whose polymorphic VT is reproducibly initiated by an infusion of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      or by exercise, a characteristic also seen with familial disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of pacing, beta blockers, and calcium channel blockers alone or in combination may be effective if the arrhythmia is pause-dependent.",
"     </li>",
"     <li>",
"      Occasional patients with frequent uniform ventricular premature beats (VPBs) triggering recurrent polymorphic VT or VF may be treated by catheter ablation of the VPBs when other methods fail.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, an implantable cardioverter-defibrillator (ICD) is often the treatment of choice because patients with polymorphic VT and minimal or no structural heart disease are at risk for sudden death and respond erratically to antiarrhythmic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/40,42\">",
"     40,42",
"    </a>",
"    ]. Similar recommendations apply to patients with idiopathic VF. Pharmacologic or ablative therapy remains necessary in addition to the ICD in order to suppress frequent arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/38/38505?source=see_link\">",
"     \"Early repolarization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     POLYMORPHIC VT IN CORONARY HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphic VT may occur during episodes of acute myocardial ischemia or in the acute phase of myocardial infarction (",
"    <a class=\"graphic graphic_waveform graphicRef54538 \" href=\"mobipreview.htm?7/6/7271\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef67322 \" href=\"mobipreview.htm?31/19/32054\">",
"     waveform 3",
"    </a>",
"    ). In some patients, the arrhythmia may be the only manifestation of ischemia (without angina or other more typical symptoms) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/43\">",
"     43",
"    </a>",
"    ]. The arrhythmia is not consistently related to electrolyte abnormalities, sinus bradycardia, preceding sinus pauses, or an abnormally long QT interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although polymorphic VT after an acute MI is usually associated with a normal QT interval, some patients (8 of 434 consecutive patients in one series) develop typical pause-dependent torsades de pointes in association with progressive QT interval prolongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/44\">",
"     44",
"    </a>",
"    ]. These events typically occur at days 3 to 11 during the healing phase of the infarct in the absence of recurrent ischemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with sustained polymorphic VT precipitating cardiac arrest, a normal QT interval, and coronary heart disease with suspected or confirmed myocardial ischemia, coronary revascularization is often an effective therapy, especially for those with normal or near normal left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/45\">",
"     45",
"    </a>",
"    ]. However, revascularization is not effective in all patients, most notably patients with significantly impaired left ventricular systolic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/46\">",
"     46",
"    </a>",
"    ]. When cardiac arrest occurs in the latter patients, ICD implantation should be considered in addition to revascularization.",
"   </p>",
"   <p>",
"    In addition to revascularization, pharmacologic anti-ischemic therapy should be considered, including beta blockers, nitrates, and calcium channel blocking agents. Suppression of acute ischemia may be accomplished with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or, in patients with coronary vasospasm, the administration of a calcium channel blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/40,43,47-49\">",
"     40,43,47-49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'Sustained ventricular tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIGITALIS TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digitalis toxicity is associated with a variety of ventricular arrhythmias, including ventricular premature beats, monomorphic VT, and ventricular fibrillation. An unusual arrhythmia sometimes associated with digitalis toxicity is the so-called \"bidirectional\" VT in which the rhythm is regular but every other beat has a different axis as it travels alternately down different conduction pathways (",
"    <a class=\"graphic graphic_waveform graphicRef71796 \" href=\"mobipreview.htm?28/24/29063\">",
"     waveform 2",
"    </a>",
"    ). In most cases, the rhythm has a right bundle branch block morphology with an alternating left and right axis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/50\">",
"     50",
"    </a>",
"    ]; however, alternating right and left bundle branch patterns may be seen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28072?source=see_link&amp;anchor=H24718477#H24718477\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\", section on 'Bidirectional ventricular tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bidirectional VT has been considered virtually pathognomonic for digitalis intoxication. However, it may also occur in patients with CPVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37641/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Catecholaminergic polymorphic VT'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summarizes the major issues concerning polymorphic ventricular tachycardia (VT) in the setting of a normal QT interval:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polymorphic VT in the course of an acute coronary syndrome is uncommon and usually reflects recurrent or ongoing ischemia. Appropriate management of the arrhythmia in this setting is not well defined, but prevention of ischemia, with revascularization if feasible, should be the primary goal. (See",
"      <a class=\"local\" href=\"#H10798824\">",
"       'Acute management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Polymorphic VT in coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polymorphic VT in patients without significant structural heart disease may be electrophysiologically similar to idiopathic ventricular fibrillation (VF). The management strategy in these patients usually involves placement of an implantable cardioverter-defibrillator (ICD), although some patients respond to beta blockers. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Sporadic polymorphic VT in the structurally normal heart'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Catecholaminergic polymorphic VT (CPVT) is a genetic disorder that presents as familial as well as sporadic cases. Risk factors for sudden death include documented VF, a family history of sudden death, and onset of symptoms in childhood (",
"      <a class=\"graphic graphic_table graphicRef64443 \" href=\"mobipreview.htm?4/30/4588\">",
"       table 1",
"      </a>",
"      ). Beta blockers are often given for primary prevention and should be used for secondary prevention, although the response is not uniform. Patients with one of the above risk factors for sudden death often receive an ICD with beta blockers (",
"      <a class=\"graphic graphic_table graphicRef59952 \" href=\"mobipreview.htm?12/2/12332\">",
"       table 2",
"      </a>",
"      ). The role of left cardiac sympathetic denervation in patients refractory to beta blocker therapy has not been defined. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Catecholaminergic polymorphic VT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based upon the available evidence and expert opinion, we suggest the following approach to the treatment of patients with catecholaminergic polymorphic ventricular tachycardia:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Immediate direct current cardioversion should be performed for life-threatening ventricular arrhythmias if hemodynamic compromise is present. (See",
"      <a class=\"local\" href=\"#H10798824\">",
"       'Acute management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend administering intravenous beta blockers for suppression of recurrent VT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10798824\">",
"       'Acute management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend avoiding competitive sports (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1021006\">",
"       'Avoidance of competitive sports'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of beta blockers for all adult patients with spontaneous or documented stress-induced ventricular arrhythmias (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Beta blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For survivors of cardiac arrest or for patients with syncope or sustained",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      despite therapy with beta blockers, we recommend placement of an implantable cardioverter-defibrillator (ICD) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6471335\">",
"       'Implantable cardioverter-defibrillators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients taking a beta blocker who have received an ICD and who continue to have stress-induced ventricular arrhythmias, we suggest the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      for further arrhythmia suppression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      may also be considered in patients who are unable to take flecainide due to coronary heart disease or intolerance. The use of all three drugs may be necessary in patients who continue to have ventricular arrhythmias on two drugs. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Flecainide'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3491591\">",
"       'Calcium channel blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest left sympathetic denervation for patients with CPVT who remain symptomatic after maximal medical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest the use of beta blockers in patients without clinical manifestations who are diagnosed in childhood based upon genetic analysis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Beta blockers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/1\">",
"      Nguyen PT, Scheinman MM, Seger J. Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. Circulation 1986; 74:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/2\">",
"      Wren C, Rowland E, Burn J, Campbell RW. Familial ventricular tachycardia: a report of four families. Br Heart J 1990; 63:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/3\">",
"      Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995; 91:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/4\">",
"      Fisher JD, Krikler D, Hallidie-Smith KA. Familial polymorphic ventricular arrhythmias: a quarter century of successful medical treatment based on serial exercise-pharmacologic testing. J Am Coll Cardiol 1999; 34:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/5\">",
"      Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/6\">",
"      Swan H, Piippo K, Viitasalo M, et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 1999; 34:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/7\">",
"      Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/8\">",
"      Laitinen PJ, Brown KM, Piippo K, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001; 103:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/9\">",
"      Lahat H, Eldar M, Levy-Nissenbaum E, et al. Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation 2001; 103:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/10\">",
"      Nof E, Lahat H, Constantini N, et al. A novel form of familial bidirectional ventricular tachycardia. Am J Cardiol 2004; 93:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/11\">",
"      Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med 2008; 358:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/12\">",
"      Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009; 119:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/13\">",
"      Choi G, Kopplin LJ, Tester DJ, et al. Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes. Circulation 2004; 110:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/14\">",
"      Richter S, Gebauer R, Hindricks G, Brugada P. A classic electrocardiographic manifestation of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol 2012; 23:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/15\">",
"      Wehrens XH, Lehnart SE, Huang F, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003; 113:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/16\">",
"      Suetomi T, Yano M, Uchinoumi H, et al. Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca&sup2;���release leading to catecholaminergic polymorphic ventricular tachycardia. Circulation 2011; 124:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/17\">",
"      Tester DJ, Spoon DB, Valdivia HH, et al. Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner's cases. Mayo Clin Proc 2004; 79:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/18\">",
"      George CH, Higgs GV, Lai FA. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res 2003; 93:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/19\">",
"      Paavola J, Viitasalo M, Laitinen-Forsblom PJ, et al. Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves. Eur Heart J 2007; 28:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/20\">",
"      Bhuiyan ZA, van den Berg MP, van Tintelen JP, et al. Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. Circulation 2007; 116:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/21\">",
"      Bauce B, Nava A, Rampazzo A, et al. Familial effort polymorphic ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy map to chromosome 1q42-43. Am J Cardiol 2000; 85:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/22\">",
"      Tiso N, Stephan DA, Nava A, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001; 10:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/23\">",
"      Tiso N, Salamon M, Bagattin A, et al. The binding of the RyR2 calcium channel to its gating protein FKBP12.6 is oppositely affected by ARVD2 and VTSIP mutations. Biochem Biophys Res Commun 2002; 299:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/24\">",
"      Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001; 69:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/25\">",
"      di Barletta MR, Viatchenko-Karpinski S, Nori A, et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 2006; 114:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/26\">",
"      Yano K, Zarain-Herzberg A. Sarcoplasmic reticulum calsequestrins: structural and functional properties. Mol Cell Biochem 1994; 135:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/27\">",
"      Nam GB, Burashnikov A, Antzelevitch C. Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation 2005; 111:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/28\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/29\">",
"      van der Werf C, Zwinderman AH, Wilde AA. Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments. Europace 2012; 14:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/30\">",
"      Swan H, Laitinen P, Kontula K, Toivonen L. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol 2005; 16:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/31\">",
"      Rosso R, Kalman JM, Rogowski O, et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007; 4:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/32\">",
"      Katz G, Khoury A, Kurtzwald E, et al. Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice. Heart Rhythm 2010; 7:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/33\">",
"      Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009; 15:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/34\">",
"      van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 2011; 57:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/35\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/36\">",
"      Garratt CJ, Elliott P, Behr E, et al. Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. Europace 2010; 12:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/37\">",
"      Atallah J, Fynn-Thompson F, Cecchin F, et al. Video-assisted thoracoscopic cardiac denervation: a potential novel therapeutic option for children with intractable ventricular arrhythmias. Ann Thorac Surg 2008; 86:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/38\">",
"      Collura CA, Johnson JN, Moir C, Ackerman MJ. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. Heart Rhythm 2009; 6:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/39\">",
"      Odero A, Bozzani A, De Ferrari GM, Schwartz PJ. Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy. Heart Rhythm 2010; 7:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/40\">",
"      Eisenberg SJ, Scheinman MM, Dullet NK, et al. Sudden cardiac death and polymorphous ventricular tachycardia in patients with normal QT intervals and normal systolic cardiac function. Am J Cardiol 1995; 75:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/41\">",
"      Tan JH, Scheinman MM. Exercise-induced polymorphic ventricular tachycardia in adults without structural heart disease. Am J Cardiol 2008; 101:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/42\">",
"      Meissner MD, Lehmann MH, Steinman RT, et al. Ventricular fibrillation in patients without significant structural heart disease: a multicenter experience with implantable cardioverter-defibrillator therapy. J Am Coll Cardiol 1993; 21:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/43\">",
"      Wolfe CL, Nibley C, Bhandari A, et al. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991; 84:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/44\">",
"      Halkin A, Roth A, Lurie I, et al. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome. J Am Coll Cardiol 2001; 38:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/45\">",
"      Kelly P, Ruskin JN, Vlahakes GJ, et al. Surgical coronary revascularization in survivors of prehospital cardiac arrest: its effect on inducible ventricular arrhythmias and long-term survival. J Am Coll Cardiol 1990; 15:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/46\">",
"      Natale A, Sra J, Axtell K, et al. Ventricular fibrillation and polymorphic ventricular tachycardia with critical coronary artery stenosis: does bypass surgery suffice? J Cardiovasc Electrophysiol 1994; 5:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/47\">",
"      Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007; 116:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/48\">",
"      Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol 2011; 34:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/49\">",
"      Dhalla AK, Wang WQ, Dow J, et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2009; 297:H1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37641/abstract/50\">",
"      Morris SN, Zipes DP. His bundle electrocardiography during bidirectional tachycardia. Circulation 1973; 48:32.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 916 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-89.218.100.194-DA315AB02B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37641=[""].join("\n");
var outline_f36_48_37641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CATECHOLAMINERGIC POLYMORPHIC VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H237249870\">",
"      ECG characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cardiac ryanodine receptor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Calsequestrin 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10798824\">",
"      Acute management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chronic management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6470945\">",
"      - Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1021006\">",
"      - Avoidance of competitive sports",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3491591\">",
"      - Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Flecainide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6471335\">",
"      - Implantable cardioverter-defibrillators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Sympathetic denervation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Society guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SPORADIC POLYMORPHIC VT IN THE STRUCTURALLY NORMAL HEART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chronic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      POLYMORPHIC VT IN CORONARY HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIGITALIS TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/916\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/916|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/22/34154\" title=\"figure 1\">",
"      Flecainide and exercise-induced ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/916|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/30/4588\" title=\"table 1\">",
"      ESC risk strat catechol poly VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/2/12332\" title=\"table 2\">",
"      ESC treatment catechol poly VT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/916|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?7/6/7271\" title=\"waveform 1\">",
"      ECG_1 Polymorphic VT in ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?28/24/29063\" title=\"waveform 2\">",
"      ECG bidirectional VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?31/19/32054\" title=\"waveform 3\">",
"      ECG_2 Polymorphic VT in ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/38/38505?source=related_link\">",
"      Early repolarization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23528?source=related_link\">",
"      Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26682?source=related_link\">",
"      Prognosis and management of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_48_37642="Chronic complications of spinal cord injury";
var content_f36_48_37642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic complications of spinal cord injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/48/37642/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/48/37642/contributors\">",
"     Gary M Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/48/37642/contributors\">",
"     Marc Wakasa, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/48/37642/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/48/37642/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/48/37642/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/48/37642/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/48/37642/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10148218\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord injury (SCI) is a common event; in the United States, the incidence of traumatic SCI is about 40 per million persons per year, with approximately 250,000 living survivors of traumatic SCI in July 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence of nontraumatic SCI is unknown, but it is estimated that it is three to four times greater than traumatic SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/2\">",
"     2",
"    </a>",
"    ]. SCI produces a wide variety of changes in systemic physiology that can lead to a number of complications, which rival the neurologic deficits in their impact on function and quality of life.",
"   </p>",
"   <p>",
"    Medical complications after SCI are both common and severe. In the Model Spinal Cord Injury Systems Database, rehospitalizations occurred in 55 percent of patients in the first year after SCI and continued at a stable rate of about 37 percent per year over the next 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/3\">",
"     3",
"    </a>",
"    ]. Genitourinary and respiratory complications and pressure ulcers were the most common reasons for hospitalization. Increased patient age and severity of the spinal cord lesion also impacted on the risk of complications requiring hospitalization.",
"   </p>",
"   <p>",
"    This topic reviews the management of common complications of chronic SCI, whether due to trauma or other conditions. Acute manifestations and complications of SCI are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIFE EXPECTANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life expectancy is reduced among survivors of spinal cord injury (SCI). Mortality rates are highest in the first year. For patients surviving at least one year after traumatic SCI, life expectancy is approximately 90 percent of normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. Higher neurologic level and severity of injury and older age at the time of SCI negatively impact survival.",
"   </p>",
"   <p>",
"    The most common causes of death after traumatic SCI are diseases of the respiratory system followed by cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. In earlier decades (prior to 1972), urinary complications were the leading cause of death. The risk of suicide is also increased among patients with SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Psychiatric complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Autonomic dysreflexia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord injuries (SCI) above T6 may be complicated by a phenomenon known as autonomic dysreflexia, a manifestation of the loss of coordinated autonomic responses to demands on heart rate and vascular tone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Uninhibited or exaggerated sympathetic responses to noxious stimuli below the level of the injury lead to diffuse vasoconstriction and hypertension. A compensatory parasympathetic response produces bradycardia and vasodilation above the level of the lesion, but this is not sufficient to reduce elevated blood pressure. SCI lesions lower than T6 do not produce this complication, because intact splanchnic innervation allows for compensatory dilatation of the splanchnic vascular bed.",
"   </p>",
"   <p>",
"    The estimated frequency of this complication is quite variable, ranging from 20 to 70 percent of patients with SCI lesions above T6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Autonomic dysreflexia is unusual within the first month of SCI but usually appears within the first year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical stimuli include bladder distention, bowel impaction, pressure sores, bone fracture, or occult visceral disturbances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Sexual activity can be a trigger. Autonomic dysreflexia can also complicate medical procedures, as well as labor and delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20634?source=see_link&amp;anchor=H22#H22\">",
"     \"Neurologic disorders complicating pregnancy\", section on 'Spinal cord injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common clinical manifestations are headache, diaphoresis, and increased blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/8\">",
"     8",
"    </a>",
"    ]. Flushing, piloerection, blurred vision, nasal obstruction, anxiety, and nausea may also occur. Bradycardia is common; however, some patients have tachycardia instead. The severity of attacks ranges from asymptomatic hypertension to hypertensive crisis complicated by profound bradycardia and cardiac arrest or intracranial hemorrhage and seizures. The severity of the SCI influences both the frequency and severity of attacks.",
"   </p>",
"   <p>",
"    Management of acute attacks includes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measuring and monitoring blood pressure.",
"     </li>",
"     <li>",
"      Immediately sitting the patient upright to orthostatically lower blood pressure.",
"     </li>",
"     <li>",
"      Removal of tight-fitting garments.",
"     </li>",
"     <li>",
"      Searching for and correcting noxious inciting stimuli. Bladder distension and fecal impaction are the most common precipitants. Bladder catheterization and evaluation for urinary tract infection should be undertaken; indwelling catheters should be checked for obstruction, and a rectal examination should be performed.",
"     </li>",
"     <li>",
"      Prompt reduction of blood pressure with a",
"      <span class=\"nowrap\">",
"       rapid-onset/short-duration",
"      </span>",
"      agent, depending on the severity of attack and response to above measures. Medications often used in this setting include nitrates (1 inch, 2 percent nitropaste),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      (10 mg PO or SL), sublingual",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      (25 mg), intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      (10 mg), and intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      (10 mg). Nitrates should be avoided in patients who may be using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      for erectile dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recognition and avoidance of inciting stimuli are important in preventing attacks.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     Nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/16/23814?source=see_link\">",
"     prazosin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    have been reported to prevent an attack when administered prophylactically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/6,7,10-12\">",
"     6,7,10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Coronary artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;With improved long-term survival, coronary artery disease (CAD) has become an increasingly important complication in SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/4\">",
"     4",
"    </a>",
"    ]. CAD risk factors, such as adverse lipid profile (low levels of high-density lipoproteins, elevated low-density lipoprotein cholesterol) and abnormal glucose metabolism (impaired glucose tolerance, insulin resistance, and diabetes) are more prevalent in chronic SCI patients than the able-bodied population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/13\">",
"     13",
"    </a>",
"    ]. Factors that contribute to the development of these disorders include decreased muscle mass, increased fat, and inactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/14\">",
"     14",
"    </a>",
"    ]. Studies suggest that the prevalence of CAD is 3 to 10 times higher in SCI patients compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, a nation-wide cohort study in Taiwan found that SCI was associated with an increased risk of stroke (HR = 2.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CAD mortality also appears to be higher among SCI patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/4\">",
"     4",
"    </a>",
"    ]. One contributing factor may be that SCI lesions above the T5 level may lead to atypical presentations for cardiac ischemia; manifestations may include autonomic dysreflexia or changes in spasticity rather than typical chest pain.",
"   </p>",
"   <p>",
"    Risk factor management and treatment for CAD are similar to that of able-bodied individuals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exercise options for SCI patients include hand-crank ergometry, hand cycling, swimming, and functional electrical stimulation of muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/16\">",
"     16",
"    </a>",
"    ]. Body weight-supported treadmill training has been reported to improve glucose regulation in incomplete SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/17\">",
"     17",
"    </a>",
"    ]. However, diminished sympathetic responses, reduced cardiac output, impaired ventilation, and decreased muscle mass lead to reduced exercise capacity in chronic SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/13\">",
"     13",
"    </a>",
"    ]. Physiologic responses to exercise, including increased heart rate, increased cardiac contractility, and vasoregulation, are also impaired with higher-level SCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;The autonomic nervous system dysfunction that results from SCI disrupts normal cardiovascular hemostasis. With SCI above the T6 level, baseline blood pressure is usually reduced, and baseline heart rate may be as low as 50 to 60 beats per minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. This is generally not a clinical problem, but may contribute to hemodynamic instability and exercise intolerance.",
"   </p>",
"   <p>",
"    Orthostatic hypotension due to peripheral vasodilatation is more common in the first several months of SCI and tends to dissipate with the development of muscle tone in the lower extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/8\">",
"     8",
"    </a>",
"    ]. However, it may also occur in chronic SCI, especially with excessive bed rest and diminished fluid intake. Gradual position changes, compression stockings, and abdominal binders decrease venous pooling and may improve orthostatic tolerance. Occasionally, increased salt intake, alpha adrenergic agonists (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    ), or mineralocorticoid agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    ) may be required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5161?source=see_link\">",
"     \"Treatment of orthostatic and postprandial hypotension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute cervical SCI is associated with a risk of cardiac arrhythmia due to excess vagal tone, as well as complicating hypoxia, hypotension, and fluid and electrolyte imbalances. Arrhythmias are much less frequent in chronic SCI. However, patients with complete cervical SCI appear to have an ongoing risk of cardiopulmonary arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PULMONARY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical and high thoracic spinal cord injury (SCI) affect respiratory muscles. The severity of ventilatory failure and requirement for assisted ventilation depends on the level and severity of the SCI. Lesser degrees of ventilatory failure may produce dyspnea and exercise intolerance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23321?source=see_link\">",
"     \"Respiratory physiologic changes following spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/28/42439?source=see_link\">",
"     \"Respiratory complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of impaired cough and difficulty mobilizing lung secretions, patients after SCI are also at increased risk for pneumonia. Although the incidence of pneumonia is highest in the first year following SCI, these patients remain at increased risk over their lifetime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/21\">",
"     21",
"    </a>",
"    ]. Older patients are at higher risk than younger patients. Efforts to prevent pneumonia include chest physiotherapy and vaccination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/28/42439?source=see_link\">",
"     \"Respiratory complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deep venous thrombosis and pulmonary embolism remain common early complications of SCI despite advances in awareness and treatment. Prophylactic use of low-molecular-weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is the treatment of choice for most patients with SCI. While there are no good clinical trial data to guide duration of treatment, we suggest that it should be continued in paralyzed patients for at least three months after SCI, after which the risk appears to approximate that of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/22\">",
"     22",
"    </a>",
"    ]. Specific regimens are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     URINARY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord injury (SCI) produces bladder dysfunction, often referred to as the neurogenic bladder. Other complications can result from this, including infections, vesicoureteral reflux, renal failure, and renal calculi.",
"   </p>",
"   <p>",
"    Urologic evaluation with regular follow-up is recommended for patients after SCI. Complications such as vesicoureteral reflux, renal failure, and nephrolithiasis may not produce symptoms, and if untreated, can have serious consequences. The frequency and specific testing involved (serum creatinine, cystoscopy, urodynamic studies, renal ultrasound) are not well defined but depend in part on the nature of the patient's urologic problems and other risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bladder dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCI disrupts the two major functions of the bladder, storage and emptying of urine. Bladder control is a complex activity requiring the coordinated function of the cerebral cortex, pontine and sacral micturition centers, and peripheral nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5832?source=see_link&amp;anchor=H12#H12\">",
"     \"Anatomy and localization of spinal cord disorders\", section on 'Autonomic fibers'",
"    </a>",
"    .) In SCI, the sensation for bladder fullness as well as motor control of bladder and sphincter function are impaired. Depending on the acuity, level, and completeness of the spinal cord lesion, a number of problems can result:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bladder or detrusor hyperactivity produces reflexive bladder emptying. Patients may be troubled by bladder spasms as well as urgency and frequency, often with incontinence. Over time, this can lead to decreased capacity of the bladder.",
"     </li>",
"     <li>",
"      Sphincter hyperactivity can impair complete emptying of the bladder.",
"     </li>",
"     <li>",
"      Detrusor sphincter dyssynergia, a combination of detrusor and sphincter hyperactivity, can lead to bladder contractions against a closed sphincter, leading to elevated bladder pressures and vesicoureteral reflux.",
"     </li>",
"     <li>",
"      Bladder flaccidity is produced in lower motor neuron injuries affecting the cauda equina or conus medullaris as well as with acute upper motor neuron injuries (spinal shock). This leads to chronic urinary retention with overflow incontinence and incomplete emptying.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients with incomplete SCI and all patients with complete SCI, regardless of the level of the lesion, require assistance with bladder function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/21\">",
"     21",
"    </a>",
"    ]. Although there are no clinical trials that guide the long-term management of bladder dysfunction in SCI, accumulated clinical experience has led to some management strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The efficacy of these approaches may be manifest by the declining incidence of urinary tract-related morbidity and mortality in SCI patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/4,21\">",
"     4,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal of a SCI bladder program is to preserve renal function while eliminating urine at regular and socially acceptable times, avoiding high bladder pressures, retention, incontinence, and infection. This should begin as early as possible after SCI, with removal of the indwelling Foley catheter.",
"   </p>",
"   <p>",
"    Clean technique intermittent catheterization (CIC) has a lower infection rate compared with the use of indwelling catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/21\">",
"     21",
"    </a>",
"    ]. CIC is performed at regular intervals, usually every four hours. A bladder volume of less than 500 cc of urine is targeted in order to avoid bladder distention, excessive intravesicular pressure, and reflux, as well as to reduce the incidence of infections. The timing of CIC and the amount of fluid intake is adjusted to reach this goal. A fluid intake restriction of two liters a day is common for patients with SCI. If present, a sensation of fullness and attempt at voluntary voiding is encouraged prior to CIC, since some incompletely injured persons will regain normal voiding function.",
"   </p>",
"   <p>",
"    Intermittent urinary incontinence is expected. Condom catheters (for men) and adult diapers are important short-term interventions. After ruling out an infection and adjusting the frequency of CIC and fluid intake, medications are considered. Urodynamic studies should be considered to assess physiology and guide pharmacologic intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticholinergic medications (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"       oxybutynin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14646?source=see_link\">",
"       tolterodine",
"      </a>",
"      ) decrease bladder tone, suppress bladder contractions, and may reduce urinary frequency and incontinence. Tricyclic antidepressants such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      have the added side effect of increasing urethral resistance tone.",
"     </li>",
"     <li>",
"      Alpha adrenergic medications (ephedrine and phenylpropanolamine) can increase bladder storage in patients with pathologic relaxation of the sphincter.",
"     </li>",
"     <li>",
"      Cholinergic medications (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25476?source=see_link\">",
"       bethanechol",
"      </a>",
"      ) may help complete bladder emptying in those with hypotonic bladders.",
"     </li>",
"     <li>",
"      Alpha-blockers (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/16/23814?source=see_link\">",
"       prazosin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36085?source=see_link\">",
"       terazosin",
"      </a>",
"      ) help sphincter relaxation, lowering bladder pressures during contraction. These can be prescribed for treatment of detrusor sphincter dyssynergia, but may aggravate hypotension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients are managed with a combination of CIC and oral anticholinergic medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients unable to perform CIC and without available caregivers, a chronic indwelling catheter may be necessary. This is associated with an increased risk of urinary tract infection (UTI) compared with CIC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/29\">",
"     29",
"    </a>",
"    ]. The indwelling catheter is changed every month to minimize infections.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     Oxybutynin",
"    </a>",
"    chloride (5 mg bid) can decrease catheter-induced bladder spasms. With indwelling catheters, there is an increased risk of prostatitis, epididymitis, and urethral stricture. Suprapubic tube placement can help minimize the risks of infection and stricture. A cystoscopy every two years is recommended to monitor for the increased incidence of bladder cancer and stone development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of detrusor injections of botulinum toxin A in patients with detrusor hyperactivity suggest that this treatment is safe and highly effective in controlling symptoms and improving quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/28,30-33\">",
"     28,30-33",
"    </a>",
"    ]. However, the optimal dose has not been determined and long-term efficacy is unknown. There have been no comparative studies with anticholinergic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/34\">",
"     34",
"    </a>",
"    ]. The use of botulinum toxin for the treatment of non-neurogenic lower urinary tract dysfunction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19336?source=see_link\">",
"     \"Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of implanted sacral nerve modulators show promise as a treatment for urinary incontinence following SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with unsatisfactory response to medical and catheter management, other treatments, bladder augmentation, urinary diversion, sphincterotomy, urethral stent, and electrical implantation devices can be considered in selected cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/2,23\">",
"     2,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infections (UTI) are common in SCI, with an incidence of 2.5 episodes per patient per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/36\">",
"     36",
"    </a>",
"    ]. The urinary tract is the most frequent source of septicemia in SCI patients and has a high mortality rate (15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. UTI is more common in women than men. Low-frequency and high-volume catheterization increase the risk of UTI, as do indwelling catheters and assisted (as opposed to self) intermittent catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/29,38,39\">",
"     29,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic UTI as manifest by fever, autonomic dysreflexia, increased spasticity, foul-smelling urine, incontinence, frequency, or dysuria warrants prompt antibiotic treatment to avoid septicemia and other complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15479?source=see_link\">",
"     \"Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=see_link\">",
"     \"Acute complicated cystitis and pyelonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic UTIs are not generally treated; nor is there a role for routine use of prophylactic antibiotics to prevent UTI in SCI patients, despite the fact that asymptomatic bacteriuria is common after SCI and is associated with a higher risk of symptomatic UTI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/38\">",
"     38",
"    </a>",
"    ]. A meta-analysis of published literature found that antibiotic prophylaxis in patients with SCI reduced asymptomatic bacteriuria but not symptomatic infections, and was associated with a twofold increase in the risk of drug-resistant bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/40\">",
"     40",
"    </a>",
"    ]. However, some individuals with recurrent UTI may benefit from prophylactic antibiotic treatment, depending on the frequency and clinical severity of the infections. In particular, the combination of frequent UTI and vesicoureteral reflux is associated with a high risk of renal failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5514?source=see_link\">",
"     \"Recurrent urinary tract infection in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other methods of reducing the incidence of UTI are under investigation and include colonization of the urinary tract with inert bacterial strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/41\">",
"     41",
"    </a>",
"    ]. Cranberry juice is believed to reduce bacterial adherence to the uroepithelium and thereby prevent UTI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/42\">",
"     42",
"    </a>",
"    ]. However, its efficacy is unproven, and the associated fluid and caloric intake may be problematic in individuals with SCI. In two small clinical trials, a cranberry supplement was found ineffective in reducing bacteriuria, pyuria, or UTI in patients with SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Urinary calculi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calculi in the kidney, ureter, or bladder are increased after SCI, especially in patients who have recurrent UTIs, indwelling catheters, and immobilization hypercalciuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Bone metabolism'",
"    </a>",
"    below.) Because of altered bladder sensation, there may not be pain to alert the clinician to ureteral obstruction. Other clinical symptoms such as increased limb spasticity and episodes of autonomic dysreflexia should suggest this as a possible diagnosis (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Autonomic dysreflexia'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The diagnosis and treatment of urinary calculi is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30695?source=see_link\">",
"     \"Options in the management of renal and ureteral stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vesicoureteral reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired function of the vesicoureteral insertion may result from high bladder pressures and recurrent UTI. The estimated incidence of this complication in SCI patients is as high as 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Because persistent reflux is associated with a higher risk of pyelonephritis and renal dysfunction, it represents a treatment imperative. If reflux persists despite the use of anticholinergic drugs and increased frequency of catheterization, placement of an indwelling catheter or a surgical procedure may be necessary. The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    may reduce phasic increases in bladder pressure caused by bladder spasms with an indwelling catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cumulative incidence of renal insufficiency increases with time since SCI and is as high as 25 percent at 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/21,48,49\">",
"     21,48,49",
"    </a>",
"    ]. Indwelling urethral catheters, vesicoureteral reflux, and advanced age are associated with the development of renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SEXUAL DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consequences of spinal cord injury (SCI) on sexual function include decreased libido, impotence, and infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Male impotence occurs in 75 percent of patients with SCI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/23\">",
"       23",
"      </a>",
"      ]. Patients with complete as opposed to incomplete injuries have the greatest incidence and severity of this complication. There are a variety of treatment options for erectile dysfunction, including medications, assistive devices, and surgically implanted prostheses.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      have documented efficacy in SCI, but are contraindicated (as are other phosphodiesterase-5 inhibitors) if there is comorbid coronary artery disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/51-56\">",
"       51-56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link\">",
"       \"Treatment of male sexual dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prevalence of male infertility in SCI is high as a consequence of erectile dysfunction, ejaculatory dysfunction,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poor sperm quality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/24,50\">",
"       24,50",
"      </a>",
"      ]. In general, male reproduction after SCI requires artificial insemination. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33481?source=see_link\">",
"       \"Evaluation of male infertility\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3610?source=see_link\">",
"       \"Treatment of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sexual responses in women may also be impaired after SCI, but ovulation and fertility are generally unaffected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/23,50\">",
"       23,50",
"      </a>",
"      ]. The lower pregnancy rates among women with SCI as compared with the general population are felt to reflect personal choice. Pregnancy in women with SCI is generally categorized as high risk because of a high rate of complications including infections and autonomic dysreflexia. This is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20634?source=see_link&amp;anchor=H22#H22\">",
"       \"Neurologic disorders complicating pregnancy\", section on 'Spinal cord injury'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel dysfunction is common and disabling after spinal cord injury (SCI) and significantly affects functional and quality of life outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. A multi-dimensional program is frequently necessary to obtain the best results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two patterns of bowel dysfunction may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/61\">",
"     61",
"    </a>",
"    ]. With injuries above the conus medullaris, neural connections between the spinal cord and bowel are maintained, resulting in hyperreflexic pelvic muscle contraction and inability to voluntarily relax the external anal sphincter. This causes constipation and fecal retention. A lower motor neuron or areflexic bowel occurs with injuries below the conus medullaris, leading to slower transit, decreased sphincter tone, and constipation with frequent incontinence.",
"   </p>",
"   <p>",
"    Because few studies have evaluated the management of this problem, recommendations are based on clinical experience and expert opinion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. With a goal of predictable and timely bowel evacuation that avoids fecal incontinence and impaction, a consistent, structured regimen is integrated into the patient's lifestyle as early as possible after SCI, using their preinjury bowel pattern as a guide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/8,50\">",
"     8,50",
"    </a>",
"    ]. A typical routine may begin at a regular time point each day (eg, 30 minutes after a meal) with insertion of a chemical stimulant rectal suppository. After several minutes, digital stimulation with slow, gentle rotation of the finger for 15 to 60 seconds is repeated every 5 to 10 minutes, until stool evacuation is complete. Abdominal massage, deep breathing, Valsalva maneuver, and forward-leaning position may assist evacuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral bowel medications (stool softener,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/41/22165?source=see_link\">",
"     docusate",
"    </a>",
"    sodium; bowel stimulants,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40276?source=see_link\">",
"     senna",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    ; bulking agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    ) are often used during the initial phase of establishing a regular bowel pattern, and are then slowly eliminated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/61\">",
"     61",
"    </a>",
"    ]. Chronic use of stimulant laxatives is associated with a number of side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=see_link&amp;anchor=H30890967#H30890967\">",
"     \"Management of chronic constipation in adults\", section on 'Other laxatives'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A regular diet is an important feature of the bowel program and should include adequate fiber intake (30 g) and relatively lower amounts of dairy products and fat content [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/8,61\">",
"     8,61",
"    </a>",
"    ]. Targets for fluid intake are often dictated by the patient's bladder status, but if possible, should be high enough to produce 2 to 3 liters of urinary output each day.",
"   </p>",
"   <p>",
"    If constipation or impaction develops, a trial of enemas, laxatives, or bulk-forming agents may be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/61\">",
"     61",
"    </a>",
"    ]. Abdominal x-rays should be considered to screen for evidence of obstruction. Diseases not related to the SCI, particularly colorectal cancer, should be excluded. Prokinetic medications (eg, cisapride,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ) are reserved for persistent, severe constipation that is unresponsive to modifications of the bowel program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/60\">",
"     60",
"    </a>",
"    ]. Some patients with severe bowel dysfunction require a colostomy. Uncontrolled observational studies suggest that regular transanal irrigation can reduce constipation and fecal incontinence and improve quality of life in some patients with chronic bowel dysfunction following SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. A new therapeutic technology, sacral electrical stimulation, is under investigation and appears promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/60\">",
"     60",
"    </a>",
"    ]. Details regarding the treatment of constipation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=see_link\">",
"     \"Management of chronic constipation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemorrhoids can be increased by the interventions (suppositories, enemas, digital stimulation) commonly used in bowel programs for SCI. Treatment includes stool softeners, minimizing trauma, topical anti-inflammatory creams, and suppositories. Hemorrhoids causing persistent bleeding, pain, or autonomic dysreflexia warrant surgical consultation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/61/6105?source=see_link\">",
"     \"Treatment of hemorrhoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serious abdominal complications (cholecystitis, upper gastrointestinal bleeding, pancreatitis, or appendicitis) account for 10 percent of deaths following SCI, with the most significant risks during the first few months after injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/18,66\">",
"     18,66",
"    </a>",
"    ]. There is an increased prevalence of gallstones in patients with chronic SCI, perhaps in relationship to denervation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/67\">",
"     67",
"    </a>",
"    ]. Sensory deficits resulting from SCI contribute to a delay in diagnosis and increased mortality associated with these complications. Vague or nonspecific symptoms such as nausea, anorexia, or autonomic dysreflexia should raise concern for occult abdominal processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The superior mesenteric artery syndrome is an unusual complication of SCI, usually in patients with cervical cord injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Weight loss leads to loss of the mesenteric fat pad and compression of the duodenum by the superior mesenteric artery, leading to symptoms of small bowel obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37799?source=see_link\">",
"     \"Superior mesenteric artery syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     BONE METABOLISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;After spinal cord injury (SCI), osteoporosis affects bones below the level of the injury and increases the risk of lower extremity fractures. In one series of 41 men, after a median of 15 years after SCI, 61 percent had osteoporosis and 34 percent had had a fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of osteoporosis is unknown; neural factors as well as disuse are believed to play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/71\">",
"     71",
"    </a>",
"    ]. Biomarkers of bone resorption are increased, beginning as early as the first week after injury, while markers of bone formation are normal or only minimally elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Some studies suggest that about two years after SCI, a new steady state level between bone resorption and formation is reestablished [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/71\">",
"     71",
"    </a>",
"    ]. Older age, higher spinal level of injury, lesser degrees of spasticity, and longer chronicity of the injury have been inconsistently associated with higher degrees of observed bone loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/21,71-75\">",
"     21,71-75",
"    </a>",
"    ]. Rates of osteoporosis among men and premenopausal women with SCI are similar; too few postmenopausal women with SCI have been included in studies to know whether this population is at additional risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, symptomatic hypercalcemia and hypercalciuria complicate early resorption of bone mass within the first few months of SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/8\">",
"     8",
"    </a>",
"    ]. Manifestations can include nausea, vomiting, anorexia, lethargy, and polyuria. There is an increased risk of nephrolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/72\">",
"     72",
"    </a>",
"    ]. Treatment is graded to severity of symptoms. Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    has been used for acute immobilization hypercalcemia after SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Over time, patients with SCI develop a specific pattern of bone abnormalities, with marked loss of bone density in the proximal tibia and femur, and relatively less bone loss in the spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/73,78\">",
"     73,78",
"    </a>",
"    ]. The impact of weight-bearing on the spine during sitting and wheelchair use may contribute to this discrepancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/72\">",
"     72",
"    </a>",
"    ]. Patients with quadriparesis may also experience bone loss in the distal forearm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In small observational and open-label, randomized studies, treatment with bisphosphonates such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/51/38709?source=see_link\">",
"     tiludronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    has been shown to attenuate bone loss in patients with SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/79-82\">",
"     79-82",
"    </a>",
"    ]. In one small, double-blind, randomized trial (31 patients), alendronate (70 mg weekly) was also shown to prevent bone loss at the hip when administered within 10 days of acute SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/83\">",
"     83",
"    </a>",
"    ]. Functional electrical stimulation has shown minimal and largely unsustained benefits in improving bone density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/72,84-86\">",
"     72,84-86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Heterotopic ossification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heterotopic ossification refers to the deposition of bone within the soft tissue around peripheral joints. This occurs in up to half of SCI patients, beginning at a mean of 12 weeks after injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/87\">",
"     87",
"    </a>",
"    ]. Although heterotopic ossification is common after SCI, only 10 to 20 percent of patients have clinical symptoms, with decreased range of motion and inflammatory symptoms in the affected joints. The large joints below the level of injury are typically affected, most commonly the hip. The pathogenesis of this phenomenon is incompletely understood, but it is believed to originate from osteoprogenitor stem cells lying dormant within the affected soft tissues. With the proper stimulus (as with hip surgery, spinal cord injury, and stroke), these stem cells may differentiate into osteoblasts that form osteoid and eventually bone. Heterotopic ossification in the setting of total hip arthroplasty is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/39/1658?source=see_link&amp;anchor=H38#H38\">",
"     \"Complications of total hip arthroplasty\", section on 'Heterotopic ossification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deep venous thrombosis, cellulitis, infection, hematoma, and tumor should be considered as alternative diagnoses for localized pain in SCI patients. Because calcification may not appear for weeks after clinical presentation, plain radiographs are of limited use in the early diagnosis. An elevated serum alkaline phosphatase level can help differentiate early heterotopic ossification from other conditions, but is not a specific finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/88\">",
"     88",
"    </a>",
"    ]. The triple phase bone scan is the most reliable test for diagnosis.",
"   </p>",
"   <p>",
"    Early administration of NSAIDs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    75 mg daily for three weeks or rofecoxib 25 mg daily for four weeks) after SCI appears to reduce the incidence of heterotopic calcification according to a 2010 systematic review that included two randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. Further research is required to identify which patients will benefit from this intervention.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    and pulse low-intensity electromagnetic field therapy may also be useful in the prevention of heterotopic ossification, but a clinical role for these modalities for this indication is not yet established.",
"   </p>",
"   <p>",
"    The initial treatments of heterotopic ossification are passive range-of-motion exercise, with the goal of maintaining joint mobility, and nonsteroidal anti-inflammatory drugs (NSAIDS). Bisphosphonates may also be useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/89\">",
"     89",
"    </a>",
"    ]. According to uncontrolled case series,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    (given intravenous for three days, followed by six months of oral therapy) reduced swelling and retarded or halted progression of heterotopic ossification, particularly if it was administered early, when bone scans were positive, but radiographs remained normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/89,92-94\">",
"     89,92-94",
"    </a>",
"    ]. Radiotherapy also appeared to limit progression in one case series of 52 patients with heterotopic ossification after SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/89,95\">",
"     89,95",
"    </a>",
"    ]. For refractory cases, surgery is a treatment option to allow functional range of movement; however, the majority of patients experience recurrence after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/96\">",
"     96",
"    </a>",
"    ]. A small retrospective study found that intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    (a bisphosphonate) prevented recurrent heterotopic ossification in patients undergoing excision surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/87\">",
"     87",
"    </a>",
"    ]. Reports of early resection in combination with drug and radiation treatment also appear promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MUSCULOSKELETAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After spinal cord injury (SCI), muscle contractures can result from reorganization of the collagen tissue matrix that occurs when the muscle lies in the shortened position for an extended period of time. Both immobility and spasticity contribute to this occurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/99\">",
"     99",
"    </a>",
"    ]. Preventive management is extremely important and should begin immediately after a SCI and continue for long-term care:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positioning. While in bed, the patient should be positioned, using pillows to minimize flexion at the hip and knee, and adduction and internal rotation at the shoulder. Wheelchair positioning should maintain normal lumbar lordosis. Frequent repositioning prevents skin breakdown as well as contractures; these complications often co-exist [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Range-of-motion exercise. Paretic extremity joints should be exercised 5 to 20 minutes daily. The intensity of exercises needed to prevent deformity varies among individuals, but the goal is maintenance of full range. Any limitation warrants investigation for heterotopic ossification, fracture, hematoma, infection, or thrombosis.",
"     </li>",
"     <li>",
"      Splinting. Upper extremity flexion contractures and ankle plantar-flexion contractures can be prevented with resting night splints or bivalve (removable) casting. The fitting and timing of splints must be adjusted based on skin and pain tolerance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goal of these interventions is to induce prolonged muscle stretching of vulnerable muscles; however, their efficacy in preventing contractures has not been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/100\">",
"     100",
"    </a>",
"    ]. Established contractures may require surgical treatment.",
"   </p>",
"   <p>",
"    Certain contractures can facilitate function. Patients with SCI at C6 level may gain improved functional hand tenodesis with finger flexion contractures that enhance prehension with wrist extension. A slight elbow flexion contracture can improve the mechanical advantage of a weakened biceps muscle.",
"   </p>",
"   <p>",
"    Repetitive over-use injuries in the upper extremities are common in SCI patients, related to transfers and wheelchair use. Rotator cuff and other tendon injuries, carpal tunnel syndrome, bursitis, and osteoarthritis are common sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/101-103\">",
"     101-103",
"    </a>",
"    ]. The shoulders are most often affected (75 percent), followed by wrists, hands, and elbows (53, 43, and 35 percent, respectively). Specific exercise programs to minimize injuries and preserve joint function can be helpful, as can the use of power wheelchairs and ergonomic assessments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/104\">",
"     104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/3/35896?source=see_link\">",
"     \"Overview of joint protection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PRESSURE ULCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure ulcers result from tissue damage due to unrelieved pressure that typically occurs over bony prominences. Shear, friction, poor nutrition, and changes in skin physiology below the level of the lesion also contribute to the development of pressure ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/21\">",
"     21",
"    </a>",
"    ]. Prevalence rates for pressure ulcers in chronic spinal cord injury (SCI) are difficult to obtain, but have been estimated at approximately 30 percent at 20 years following SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/21,105\">",
"     21,105",
"    </a>",
"    ]. Both the level and severity of SCI impact significantly on the risk of developing a pressure ulcer.",
"   </p>",
"   <p>",
"    Multiple pressure ulcers occur in more than one-third of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/20\">",
"     20",
"    </a>",
"    ]. The most common locations of pressure ulcers in the SCI patient are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ischium &ndash; 31 percent",
"     </li>",
"     <li>",
"      Trochanter - 26 percent",
"     </li>",
"     <li>",
"      Sacrum - 18 percent",
"     </li>",
"     <li>",
"      Heel - 5 percent",
"     </li>",
"     <li>",
"      Malleolus - 4 percent",
"     </li>",
"     <li>",
"      Feet - 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preventative strategies include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Examining skin over areas most vulnerable to ulcer formation daily",
"     </li>",
"     <li>",
"      Avoiding immobility and excess moisture in susceptible regions",
"     </li>",
"     <li>",
"      Use of pressure-relieving wheelchairs, cushions, and other devices",
"     </li>",
"     <li>",
"      Maintenance of adequate nutritional intake and weight",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Comprehensive treatment includes assessment of health status and status of the ulcer. An ulcer treatment plan consists of cleansing, debridement, nutritional support, and management of tissue loads. The prevention and treatment of pressure ulcers are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1049?source=see_link\">",
"     \"Prevention of pressure ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37064?source=see_link\">",
"     \"Treatment of pressure ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SPASTICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spasticity is believed to result from disruption of descending inhibitory modulation of the alpha motor neurons, producing hyperexcitability, which is manifest as increased muscle tone and spasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Negative effects of spasticity include pain, decreased mobility, contractures, and muscle spasms, all of which can interfere with sleep and activities of daily living. At the same time, spasticity has some positive aspects: increased tone can facilitate some functional activities, including standing and transfers. Increased muscle tone may also promote venous return, minimizing deep venous thrombosis and orthostatic hypotension.",
"   </p>",
"   <p>",
"    Abolishing spasticity is difficult and not necessarily desirable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/107\">",
"     107",
"    </a>",
"    ]. Treatment should be directed at minimizing spasticity as it relates to functional impairment and should follow a graded approach, starting with the least invasive approach. Nonpharmacologic treatments include physical therapy. Regular stretching and use of braces can help maintain range of movement and prevent contractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/107\">",
"     107",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Musculoskeletal complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Oral medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Though often prescribed for spasticity, the evidence of efficacy for commonly used oral medications is not substantial, side effects are often dose limiting, and the relative benefit of these treatments has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/108\">",
"     108",
"    </a>",
"    ]. With all medications, slow dose escalation may mitigate against adverse side effects, which include sedation, dry mouth, dizziness, and weakness. Dosing guidelines and adverse effects of these medications are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef63526 \" href=\"mobipreview.htm?39/56/40843\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"       Baclofen",
"      </a>",
"      , a GABA-B agonist, is the most commonly used oral medication for spasticity, despite the paucity of evidence-based support for its efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/108-110\">",
"       108-110",
"      </a>",
"      ]. Although adverse effects of sedation and weakness can be dose-limiting, baclofen is safe for long-term use, without evidence of tolerance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/107\">",
"       107",
"      </a>",
"      ]. Abrupt discontinuation of baclofen is advised against because of potential withdrawal symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=see_link&amp;anchor=H16#H16\">",
"       \"Neuroleptic malignant syndrome\", section on 'Other drug-related syndromes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"       Tizanidine",
"      </a>",
"      , a centrally acting alpha-2 adrenergic agonist, was compared with placebo in one of the largest studies of spasticity treatment in spinal cord injury (SCI) patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/111\">",
"       111",
"      </a>",
"      ]. Among the 78 of 124 randomized patients who completed the study, tizanidine produced a significant reduction in spasticity, but had no effect on activities of daily living and other functional assessments. Sedation was the most common limiting side effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"       Diazepam",
"      </a>",
"      , a GABA-A agonist, is the most commonly used benzodiazepine for spasticity, often in conjunction with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"       tizanidine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/106,113\">",
"       106,113",
"      </a>",
"      ]. Sedation, confusion, hypotension, and gastrointestinal symptoms can be dose-limiting. Diazepam or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      may be particularly useful in controlling nighttime spasms.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/22/22887?source=see_link\">",
"       Dantrolene",
"      </a>",
"      sodium differs from other medications discussed in that it acts peripherally, inhibiting calcium release from sarcoplasmic reticulum of the muscle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/107\">",
"       107",
"      </a>",
"      ]. More than the other agents used, it produces weakness of both affected and unaffected muscles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/110\">",
"       110",
"      </a>",
"      ]. Its potential for hepatotoxicity requires liver function test monitoring every three to six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Less commonly used oral medications used for spasticity include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      , cannabinoids, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/25/19862?source=see_link\">",
"       cyproheptadine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef63526 \" href=\"mobipreview.htm?39/56/40843\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/106,107,114-116\">",
"       106,107,114-116",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Intrathecal baclofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     Baclofen",
"    </a>",
"    is centrally acting, but crosses the blood brain barrier ineffectively, limiting its bioavailability when taken orally. Intrathecal baclofen allows for four-times the amount of baclofen to be delivered to the spinal cord with 1 percent of the oral dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/18,107\">",
"     18,107",
"    </a>",
"    ]. Treatment is administered by a surgically implanted, computer-programmed infusion pump with a catheter extending into the intrathecal space. In general, patients undergo a trial of intrathecal baclofen infusions prior to pump implantation. Although systemic side effects of baclofen are generally avoided with this approach, complications of intrathecal baclofen therapy can include spinal fluid leaks, hemorrhage, infection, catheter dislodgement, and pump failure.",
"   </p>",
"   <p>",
"    Two double-blind crossover studies compared intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    infusion with saline placebo in patients after SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. Patients treated with intrathecal baclofen had both reduced spasticity and improved disability. This approach may also reduce pain associated with spasticity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Injection techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemodenervation provides a localized treatment of spasticity within a muscle or muscle group. Although systemic side effects associated with medications are avoided, the large number of muscles involved in SCI limit the use of this approach for these patients. However, in some patients, targeted relief of spasticity in certain muscle groups can improve ambulation and other specific functions. Agents include botulinum toxin, phenol, and alcohol.",
"   </p>",
"   <p>",
"    Botulinum toxin acts at the neuromuscular junction, preventing acetylcholine release. Treatment effects last a few months, requiring repeated injections. Side effects include muscle weakness and injection-site reactions, but in general this treatment is safe and effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/120\">",
"     120",
"    </a>",
"    ]. One randomized study compared botulinum toxin injections to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    for upper limb spasticity following stroke or traumatic brain injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/112\">",
"     112",
"    </a>",
"    ]. Botulinum toxin treatments were more effective in reducing tone and were associated with fewer adverse effects than tizanidine. However, spasticity is not as yet an FDA-approved indication for botulinum toxin.",
"   </p>",
"   <p>",
"    The US Food and Drug Administration has issued a warning about the possibility of life-threatening systemic adverse effects from local botulinum toxin injections. The warning was based on reports of severe difficulty swallowing or breathing in several patients and occurred mostly in children with cerebral palsy receiving local injections for limb spasticity. Some of these complications appear be caused by inadvertent overdosing, because potency determinations expressed in \"units\" varied among botulinum toxin products. In response, the FDA mandated changes in drug names that were designed to emphasize these differences in drug potency and prevent medication errors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/121\">",
"     121",
"    </a>",
"    ]. Providers should be alert for the potential of systemic effects, including dysphagia, dysphonia, weakness, or dyspnea, occurring up to several weeks after treatment.",
"   </p>",
"   <p>",
"    Phenol and ethanol nerve blocks essentially superimpose a lower motor neuron lesion on the upper motor neuron deficit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Weakness, injection site pain, phlebitis, permanent nerve damage, and sensory dysesthesia can be problematic complications of this procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical destructive procedures, rhizotomy, myelotomy, cordotomy, and cordectomy are reserved for refractory cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/18\">",
"     18",
"    </a>",
"    ]. Orthopedic procedures involving the muscle or tendon can be used to treat established contractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PAIN SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant number of patients develop a chronic pain syndrome several months to years after spinal cord injury (SCI). Reported prevalences vary considerably. On average, two-thirds of patients suffer chronic pain and about one-quarter to one-third of patients have severe pain that significantly affects quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/110,122\">",
"     110,122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurogenic pain after SCI can be both spontaneous and stimulus-evoked, is often poorly localized, and is often described as burning, stabbing, or electrical in quality. Hyperesthesia is a common component. These qualities can help distinguish neurogenic from musculoskeletal pain (usually dull, aching, and well-localized) that can result from a number of complications common to SCI patients. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Musculoskeletal complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although neurogenic pain appears to be associated with neuronal hyperexcitability, mechanisms are poorly understood. Two types of neurogenic pain syndromes are recognized: at-level pain (ie, pain in segments at the level of SCI) and below-level pain. These are believed to have different neuroanatomic and pathophysiologic bases, with injury to nerve roots and dorsal gray matter causing at-level pain, and injury to spinothalamic tracts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thalamic deafferentation responsible for below-level pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/123\">",
"     123",
"    </a>",
"    ]. Development of at-level pain should provoke an evaluation for post-traumatic syringomyelia, with which it is associated. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Syringomyelia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Medical treatments are often unsatisfactory; antidepressant, antiepileptic, and standard analgesic medications are tried, often in combination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiepileptic drugs are believed to improve neuropathic pain by suppressing abnormal neuronal hyperexcitability. Only a few randomized trials have studied some of these medications (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ) in SCI; most do not support their efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/124-127\">",
"       124-127",
"      </a>",
"      ]. One randomized study of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      (150 to 600 mg daily) among 137 patients after SCI found improvements in blinded assessments of pain scores as well as disturbed sleep and anxiety [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/128\">",
"       128",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antidepressant medications are also used in a variety of central and peripheral neuropathic pain syndromes. Randomized trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      in SCI have not demonstrated efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/127,129,130\">",
"       127,129,130",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Opiates may provide relief in anecdotal reports, but side effects, tolerance, and dependence are significant issues [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/131\">",
"       131",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is reasonable to believe that non-oral routes of administration may provide better efficacy with fewer side effects; however, evidence supporting these therapies is somewhat limited in SCI. Therapies have included intrathecal administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/132,133\">",
"     132,133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Invasive treatments, including deep brain stimulation, motor cortex stimulation, cordotomy, and dorsal root entry zone lesions have been tried, again without substantive evidence of success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/110,134\">",
"     110,134",
"    </a>",
"    ]. In the absence of good therapies, it is not unreasonable to also consider nontraditional treatments such as acupuncture and biofeedback [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Details regarding dosing regimens, side effects, and other aspects of chronic pain management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     NEUROLOGIC DETERIORATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Syringomyelia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A delayed progressive intramedullary cystic degeneration complicates 3 to 4 percent of traumatic spinal cord injury (SCI) as well as other acute myelopathies. The interval since SCI can vary from several months to many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/135\">",
"     135",
"    </a>",
"    ]. Postulated mechanisms include scarring with obstruction of CSF flow and altered tissue compliance leading to expansion of the central canal and compression of surrounding cord tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/136\">",
"     136",
"    </a>",
"    ]. Symptoms are consistent with a progressive myelopathy and include worsening motor, sensory, bowel, and bladder deficits and pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/135\">",
"     135",
"    </a>",
"    ]. Arachnoiditis, cord compression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a narrowed spinal canal, and bony deformity, especially kyphosis, seem to be risk factors for progressive enlargement of the cyst and neurologic deterioration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/137-140\">",
"     137-140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An asymptomatic syrinx is a common incidental finding on neuroimaging in SCI patients. This entity usually has a benign prognosis, and likely represents a focal area of liquefaction necrosis of cord tissue.",
"   </p>",
"   <p>",
"    Treatment is aimed at reducing expansile intracystic pressure and improving CSF flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/135\">",
"     135",
"    </a>",
"    ]. Surgical approaches include shunt placement, lysis of subarachnoid adhesions, cyst fenestration, and dural augmentation. Extradural decompression is anecdotally reported to be helpful when there is significant bone deformity and compression of the spinal canal with restriction of spinal fluid circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/141,142\">",
"     141,142",
"    </a>",
"    ]. Unfortunately, long-term treatment benefits are seen in less than half of patients, and shunt failure is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/142,143\">",
"     142,143",
"    </a>",
"    ]. Pain may be more responsive to intervention than are motor symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/144,145\">",
"     144,145",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Progressive posttraumatic myelomalacic myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Also known as the marshy cord syndrome, progressive posttraumatic myelomalacic myelopathy is a less frequent complication of SCI and is characterized pathologically by microcysts, reactive gliosis, and meningeal thickening. Adhesions and cord tethering appear to be causally related; surgical untethering and duraplasty with expansion of the subarachnoid space can lead to clinical improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/135,146\">",
"     135,146",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PSYCHIATRIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial complications associated with spinal cord injury (SCI) include depression, suicide, drug addiction, and divorce [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Between 20 to 45 percent of patients are depressed after traumatic SCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/8,147\">",
"     8,147",
"    </a>",
"    ]. This symptom often emerges early on, within the first month after SCI, and is not closely tied to the severity of injury. Patients with SCI have a four to five times higher rate of suicide compared to age-matched population samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/5,148\">",
"     5,148",
"    </a>",
"    ]. Suicide is a leading cause of death in traumatic SCI patients younger than 55 years; 75 percent of suicides occur within the first five years of injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/8\">",
"     8",
"    </a>",
"    ]. Similar rates of depression and suicide are observed after transverse myelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/149\">",
"     149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of its high prevalence and serious consequences, patients with SCI should be regularly screened for symptoms of depression. High levels of pain and lack of social support identify patients at high risk for depression and suicidality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depression and anxiety following SCI should be treated; it should not be assumed that symptoms are a \"normal\" reaction to the circumstances and do not require treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/8\">",
"     8",
"    </a>",
"    ]. Recommended interventions include psychologic counseling, pharmacologic intervention, and peer support groups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     THERMOREGULATORY DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disrupted autonomic pathways following spinal cord injury (SCI) can lead to impaired vasomotor and sudomotor responses in regions of insensate skin, reduced thermoregulatory effector response for a given core temperature, and loss of skeletal muscle pump activity from paralyzed limbs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/150\">",
"     150",
"    </a>",
"    ]. Consequences can include hyperthermia during exercise or high ambient heat and hypothermia in lower ambient heat. There can be a blunted fever or a hypothermic response to infection. Others have noted episodes of hyperthermia or hypothermia in the absence of infection or environmental temperature change in SCI patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     FUNCTIONAL DEFICITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level and completeness of the spinal cord injury (SCI) are the principal determinants of the needs, goals, and expectations in functional abilities. Age, general health, body habitus, concurrent injuries, spinal instrumentation, intelligence, and motivation also influence recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functional recovery after a SCI begins in the acute care setting as soon as the patient is medically stable with range-of-motion and resistive exercise, upright positioning, and transfer work. In the inpatient rehabilitation setting, physical and occupational therapists experienced in SCI rehabilitation develop individualized programs that emphasize strengthening, joint protection, and compensatory strategies, combined with creative use of assistive devices and equipment to maximize function. Despite evolving technological advances, the simplest traditional approaches are often the best [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general expectations for functional recovery based on motor level are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef73350 \" href=\"mobipreview.htm?42/53/43868\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/48/37642/abstract/153\">",
"     153",
"    </a>",
"    ]. These assume an uncomplicated, complete SCI followed by appropriate rehabilitation interventions in a healthy, motivated individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/0/16386?source=see_link\">",
"       \"Patient information: Neurogenic bladder in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/53/27475?source=see_link\">",
"       \"Patient information: Paraplegia and quadriplegia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical complications after spinal cord injury (SCI) are both common and severe, contributing to a high rehospitalization rate and decreased life expectancy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Life expectancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autonomic dysreflexia can complicate SCI above T6. This is an exaggerated sympathetic response characterized by headache, diaphoresis, and increased blood pressure that occurs with noxious stimuli such as pain from bladder distension, constipation, or pressure sores. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Autonomic dysreflexia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with SCI also have an increased incidence of CAD. Hemodynamic instability and cardiac arrhythmias can be problematic in the acute and subacute SCI and are less frequent problems in chronic SCI. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cardiovascular complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The severity of ventilatory failure and requirement for assisted ventilation depends on the level and severity of the SCI. Lesser degrees of ventilatory failure may produce dyspnea and exercise intolerance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23321?source=see_link\">",
"       \"Respiratory physiologic changes following spinal cord injury\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/28/42439?source=see_link\">",
"       \"Respiratory complications of spinal cord injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An increase risk of pneumonia is highest in the first year following SCI, but patients remain at increased risk over their lifetime. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/28/42439?source=see_link\">",
"       \"Respiratory complications of spinal cord injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prophylactic use of low-molecular-weight",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      to prevent deep venous thrombosis and pulmonary embolism should be continued for at least three months after SCI, after which the risk appears to approximate that of the general population. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      SCI produces bladder dysfunction, often referred to as the neurogenic bladder. Other complications can result from this, including infections, vesicoureteral reflux, renal failure, and renal calculi. Clean intermittent catheterization, supplemented by medications as needed is the usual initial treatment. Some patients require a chronic indwelling catheter. Botulinum toxin and sacral nerve modulators are being investigated as alternative treatment options. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Urinary complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sexual dysfunction after SCI can include decreased libido, impotence, and infertility. Erectile dysfunction may respond to treatment with a phosphodiesterase-5 inhibitor. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Sexual dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bowel dysfunction after SCI usually requires treatment with a bowel evacuation protocol and a multi-dimensional approach. A regular diet that includes adequate fiber is an important part of management. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Gastrointestinal complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteoporosis affects bones below the level of the SCI and increases the risk of fracture. The role of bisphosphonates in this setting is under investigation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Bone metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Positioning and mobilization can help ameliorate contractures and pressure ulcers after SCI. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Musculoskeletal complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Pressure ulcers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spasticity is common after SCI and has positive as well as negative effects. Treatment is empiric and is aimed at minimizing pain while maximizing function. Options include oral medication, intrathecal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      , botulinum toxin, and nerve blocks. Refractory spasticity may require surgery. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Spasticity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurogenic pain after SCI is often refractory but may respond to standard analgesic therapy, antiepileptic drug therapy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antidepressant therapy. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Pain syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depression frequently complicates SCI; patients are at high risk for suicidality and should be monitored. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Psychiatric complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional neurologic deficits are determined by the level and completeness of the SCI and are ameliorated by appropriate rehabilitation interventions. If patients experience neurologic decline, neuroimaging is indicated to exclude syringomyelia, posttraumatic myelomalacic myelopathy, or other neurologic pathology. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Functional deficits'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Neurologic deterioration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Spinal Cord Injury Statistical Center, Birmingham, AL. Annual Report for the Model Spinal Cord Injury Care Systems, Birmingham, AL 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/2\">",
"      McDonald JW, Sadowsky C. Spinal-cord injury. Lancet 2002; 359:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/3\">",
"      Cardenas DD, Hoffman JM, Kirshblum S, McKinley W. Etiology and incidence of rehospitalization after traumatic spinal cord injury: a multicenter analysis. Arch Phys Med Rehabil 2004; 85:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/4\">",
"      Frankel HL, Coll JR, Charlifue SW, et al. Long-term survival in spinal cord injury: a fifty year investigation. Spinal Cord 1998; 36:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/5\">",
"      Hagen EM, Lie SA, Rekand T, et al. Mortality after traumatic spinal cord injury: 50 years of follow-up. J Neurol Neurosurg Psychiatry 2010; 81:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/6\">",
"      Bycroft J, Shergill IS, Chung EA, et al. Autonomic dysreflexia: a medical emergency. Postgrad Med J 2005; 81:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/7\">",
"      Karlsson AK. Autonomic dysreflexia. Spinal Cord 1999; 37:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/8\">",
"      Kirshblum SC, Priebe MM, Ho CH, et al. Spinal cord injury medicine. 3. Rehabilitation phase after acute spinal cord injury. Arch Phys Med Rehabil 2007; 88:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/9\">",
"      Helkowski WM, Ditunno JF Jr, Boninger M. Autonomic dysreflexia: incidence in persons with neurologically complete and incomplete tetraplegia. J Spinal Cord Med 2003; 26:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/10\">",
"      Chancellor MB, Erhard MJ, Hirsch IH, Stass WE Jr. Prospective evaluation of terazosin for the treatment of autonomic dysreflexia. J Urol 1994; 151:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/11\">",
"      Vaidyanathan S, Soni BM, Sett P, et al. Pathophysiology of autonomic dysreflexia: long-term treatment with terazosin in adult and paediatric spinal cord injury patients manifesting recurrent dysreflexic episodes. Spinal Cord 1998; 36:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/12\">",
"      Lindan R, Leffler EJ, Kedia KR. A comparison of the efficacy of an alpha-I-adrenergic blocker in the slow calcium channel blocker in the control of autonomic dysreflexia. Paraplegia 1985; 23:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/13\">",
"      Myers J, Lee M, Kiratli J. Cardiovascular disease in spinal cord injury: an overview of prevalence, risk, evaluation, and management. Am J Phys Med Rehabil 2007; 86:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/14\">",
"      Bauman WA, Spungen AM. Metabolic changes in persons after spinal cord injury. Phys Med Rehabil Clin N Am 2000; 11:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/15\">",
"      Wu JC, Chen YC, Liu L, et al. Increased risk of stroke after spinal cord injury: a nationwide 4-year follow-up cohort study. Neurology 2012; 78:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/16\">",
"      Jacobs PL, Nash MS. Exercise recommendations for individuals with spinal cord injury. Sports Med 2004; 34:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/17\">",
"      Phillips SM, Stewart BG, Mahoney DJ, et al. Body-weight-support treadmill training improves blood glucose regulation in persons with incomplete spinal cord injury. J Appl Physiol 2004; 97:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/18\">",
"      McKinley WO, Gittler MS, Kirshblum SC, et al. Spinal cord injury medicine. 2. Medical complications after spinal cord injury: Identification and management. Arch Phys Med Rehabil 2002; 83:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/19\">",
"      Franga DL, Hawkins ML, Medeiros RS, Adewumi D. Recurrent asystole resulting from high cervical spinal cord injuries. Am Surg 2006; 72:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/20\">",
"      Chen D, Apple DF Jr, Hudson LM, Bode R. Medical complications during acute rehabilitation following spinal cord injury--current experience of the Model Systems. Arch Phys Med Rehabil 1999; 80:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/21\">",
"      McKinley WO, Jackson AB, Cardenas DD, DeVivo MJ. Long-term medical complications after traumatic spinal cord injury: a regional model systems analysis. Arch Phys Med Rehabil 1999; 80:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/22\">",
"      Ploumis A, Ponnappan RK, Maltenfort MG, et al. Thromboprophylaxis in patients with acute spinal injuries: an evidence-based analysis. J Bone Joint Surg Am 2009; 91:2568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/23\">",
"      Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. Spine (Phila Pa 1976) 2001; 26:S129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/24\">",
"      Chiodo AE, Scelza WM, Kirshblum SC, et al. Spinal cord injury medicine. 5. Long-term medical issues and health maintenance. Arch Phys Med Rehabil 2007; 88:S76.",
"     </a>",
"    </li>",
"    <li>",
"     Nesathurai S. Bladder management. In: The Rehabilitation of People with Spinal Cord Injury, Nesathurai S (Ed), Arbuckle Academic Publishers, Boston 1999. p.39.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/26\">",
"      Jamison J, Maguire S, McCann J. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database Syst Rev 2011; :CD004375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/27\">",
"      Cameron AP, Rodriguez GM, Schomer KG. Systematic review of urological followup after spinal cord injury. J Urol 2012; 187:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/28\">",
"      Benarroch EE. Neural control of the bladder: recent advances and neurologic implications. Neurology 2010; 75:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/29\">",
"      Shekelle PG, Morton SC, Clark KA, et al. Systematic review of risk factors for urinary tract infection in adults with spinal cord dysfunction. J Spinal Cord Med 1999; 22:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/30\">",
"      Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007; 62:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/31\">",
"      Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/32\">",
"      Gallien P, Reymann JM, Amarenco G, et al. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 2005; 76:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/33\">",
"      Herschorn S, Gajewski J, Ethans K, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol 2011; 185:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/34\">",
"      Duthie JB, Vincent M, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011; :CD005493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/35\">",
"      Sievert KD, Amend B, Gakis G, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol 2010; 67:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/36\">",
"      Siroky MB. Pathogenesis of bacteriuria and infection in the spinal cord injured patient. Am J Med 2002; 113 Suppl 1A:67S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/37\">",
"      Waites KB, Canupp KC, Chen Y, et al. Bacteremia after spinal cord injury in initial versus subsequent hospitalizations. J Spinal Cord Med 2001; 24:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/38\">",
"      Bakke A, Vollset SE. Risk factors for bacteriuria and clinical urinary tract infection in patients treated with clean intermittent catheterization. J Urol 1993; 149:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/39\">",
"      Esclar&iacute;n De Ruz A, Garc&iacute;a Leoni E, Herruzo Cabrera R. Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol 2000; 164:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/40\">",
"      Morton SC, Shekelle PG, Adams JL, et al. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. Arch Phys Med Rehabil 2002; 83:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/41\">",
"      Hull R, Rudy D, Donovan W, et al. Urinary tract infection prophylaxis using Escherichia coli 83972 in spinal cord injured patients. J Urol 2000; 163:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/42\">",
"      Reid G, Hsiehl J, Potter P, et al. Cranberry juice consumption may reduce biofilms on uroepithelial cells: pilot study in spinal cord injured patients. Spinal Cord 2001; 39:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/43\">",
"      Linsenmeyer TA, Harrison B, Oakley A, et al. Evaluation of cranberry supplement for reduction of urinary tract infections in individuals with neurogenic bladders secondary to spinal cord injury. A prospective, double-blinded, placebo-controlled, crossover study. J Spinal Cord Med 2004; 27:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/44\">",
"      Waites KB, Canupp KC, Armstrong S, DeVivo MJ. Effect of cranberry extract on bacteriuria and pyuria in persons with neurogenic bladder secondary to spinal cord injury. J Spinal Cord Med 2004; 27:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/45\">",
"      Foley SJ, McFarlane JP, Shah PJ. Vesico-ureteric reflux in adult patients with spinal injury. Br J Urol 1997; 79:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/46\">",
"      Ku JH, Choi WJ, Lee KY, et al. Complications of the upper urinary tract in patients with spinal cord injury: a long-term follow-up study. Urol Res 2005; 33:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/47\">",
"      Kim YH, Bird ET, Priebe M, Boone TB. The role of oxybutynin in spinal cord injured patients with indwelling catheters. J Urol 1997; 158:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/48\">",
"      Weld KJ, Wall BM, Mangold TA, et al. Influences on renal function in chronic spinal cord injured patients. J Urol 2000; 164:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/49\">",
"      Giannantoni A, Scivoletto G, Di Stasi SM, et al. Clean intermittent catheterization and prevention of renal disease in spinal cord injury patients. Spinal Cord 1998; 36:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/50\">",
"      Benevento BT, Sipski ML. Neurogenic bladder, neurogenic bowel, and sexual dysfunction in people with spinal cord injury. Phys Ther 2002; 82:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/51\">",
"      Derry FA, Dinsmore WW, Fraser M, et al. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 1998; 51:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/52\">",
"      Giuliano F, Hultling C, El Masry WS, et al. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group. Ann Neurol 1999; 46:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/53\">",
"      Maytom MC, Derry FA, Dinsmore WW, et al. A two-part pilot study of sildenafil (VIAGRA) in men with erectile dysfunction caused by spinal cord injury. Spinal Cord 1999; 37:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/54\">",
"      Schmid DM, Schurch B, Hauri D. Sildenafil in the treatment of sexual dysfunction in spinal cord-injured male patients. Eur Urol 2000; 38:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/55\">",
"      Giuliano F, Sanchez-Ramos A, L&ouml;chner-Ernst D, et al. Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury. Arch Neurol 2007; 64:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/56\">",
"      Giuliano F, Rubio-Aurioles E, Kennelly M, et al. Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injury. Spine (Phila Pa 1976) 2008; 33:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/57\">",
"      Glickman S, Kamm MA. Bowel dysfunction in spinal-cord-injury patients. Lancet 1996; 347:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/58\">",
"      Levi R, Hultling C, Nash MS, Seiger A. The Stockholm spinal cord injury study: 1. Medical problems in a regional SCI population. Paraplegia 1995; 33:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/59\">",
"      Stone JM, Nino-Murcia M, Wolfe VA, Perkash I. Chronic gastrointestinal problems in spinal cord injury patients: a prospective analysis. Am J Gastroenterol 1990; 85:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/60\">",
"      Krassioukov A, Eng JJ, Claxton G, et al. Neurogenic bowel management after spinal cord injury: a systematic review of the evidence. Spinal Cord 2010; 48:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/61\">",
"      Lynch AC, Antony A, Dobbs BR, Frizelle FA. Bowel dysfunction following spinal cord injury. Spinal Cord 2001; 39:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/62\">",
"      Coggrave M, Wiesel PH, Norton C. Management of faecal incontinence and constipation in adults with central neurological diseases. Cochrane Database Syst Rev 2006; :CD002115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/63\">",
"      Christensen P, Bazzocchi G, Coggrave M, et al. Outcome of transanal irrigation for bowel dysfunction in patients with spinal cord injury. J Spinal Cord Med 2008; 31:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/64\">",
"      Del Popolo G, Mosiello G, Pilati C, et al. Treatment of neurogenic bowel dysfunction using transanal irrigation: a multicenter Italian study. Spinal Cord 2008; 46:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/65\">",
"      Faaborg PM, Christensen P, Kvitsau B, et al. Long-term outcome and safety of transanal colonic irrigation for neurogenic bowel dysfunction. Spinal Cord 2009; 47:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/66\">",
"      Strauther GR, Longo WE, Virgo KS, Johnson FE. Appendicitis in patients with previous spinal cord injury. Am J Surg 1999; 178:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/67\">",
"      Moonka R, Stiens SA, Resnick WJ, et al. The prevalence and natural history of gallstones in spinal cord injured patients. J Am Coll Surg 1999; 189:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/68\">",
"      Laffont I, Bensmail D, Rech C, et al. Late superior mesenteric artery syndrome in paraplegia: case report and review. Spinal Cord 2002; 40:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/69\">",
"      Wilkinson R, Huang CT. Superior mesenteric artery syndrome in traumatic paraplegia: a case report and literature review. Arch Phys Med Rehabil 2000; 81:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/70\">",
"      Lazo MG, Shirazi P, Sam M, et al. Osteoporosis and risk of fracture in men with spinal cord injury. Spinal Cord 2001; 39:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/71\">",
"      Jiang SD, Dai LY, Jiang LS. Osteoporosis after spinal cord injury. Osteoporos Int 2006; 17:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/72\">",
"      Ma&iuml;moun L, Fattal C, Micallef JP, et al. Bone loss in spinal cord-injured patients: from physiopathology to therapy. Spinal Cord 2006; 44:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/73\">",
"      Shojaei H, Soroush MR, Modirian E. Spinal cord injury-induced osteoporosis in veterans. J Spinal Disord Tech 2006; 19:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/74\">",
"      Garland DE, Adkins RH, Kushwaha V, Stewart C. Risk factors for osteoporosis at the knee in the spinal cord injury population. J Spinal Cord Med 2004; 27:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/75\">",
"      Sabo D, Blaich S, Wenz W, et al. Osteoporosis in patients with paralysis after spinal cord injury. A cross sectional study in 46 male patients with dual-energy X-ray absorptiometry. Arch Orthop Trauma Surg 2001; 121:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/76\">",
"      Massagli TL, Cardenas DD. Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. Arch Phys Med Rehabil 1999; 80:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/77\">",
"      Kedlaya D, Brandstater ME, Lee JK. Immobilization hypercalcemia in incomplete paraplegia: successful treatment with pamidronate. Arch Phys Med Rehabil 1998; 79:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/78\">",
"      Reiter AL, Volk A, Vollmar J, et al. Changes of basic bone turnover parameters in short-term and long-term patients with spinal cord injury. Eur Spine J 2007; 16:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/79\">",
"      Chappard D, Minaire P, Privat C, et al. Effects of tiludronate on bone loss in paraplegic patients. J Bone Miner Res 1995; 10:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/80\">",
"      Pearson EG, Nance PW, Leslie WD, Ludwig S. Cyclical etidronate: its effect on bone density in patients with acute spinal cord injury. Arch Phys Med Rehabil 1997; 78:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/81\">",
"      Nance PW, Schryvers O, Leslie W, et al. Intravenous pamidronate attenuates bone density loss after acute spinal cord injury. Arch Phys Med Rehabil 1999; 80:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/82\">",
"      Zehnder Y, Risi S, Michel D, et al. Prevention of bone loss in paraplegics over 2 years with alendronate. J Bone Miner Res 2004; 19:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/83\">",
"      Gilchrist NL, Frampton CM, Acland RH, et al. Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2007; 92:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/84\">",
"      BeDell KK, Scremin AM, Perell KL, Kunkel CF. Effects of functional electrical stimulation-induced lower extremity cycling on bone density of spinal cord-injured patients. Am J Phys Med Rehabil 1996; 75:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/85\">",
"      Clark JM, Jelbart M, Rischbieth H, et al. Physiological effects of lower extremity functional electrical stimulation in early spinal cord injury: lack of efficacy to prevent bone loss. Spinal Cord 2007; 45:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/86\">",
"      Giangregorio L, McCartney N. Bone loss and muscle atrophy in spinal cord injury: epidemiology, fracture prediction, and rehabilitation strategies. J Spinal Cord Med 2006; 29:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/87\">",
"      Schuetz P, Mueller B, Christ-Crain M, et al. Amino-bisphosphonates in heterotopic ossification: first experience in five consecutive cases. Spinal Cord 2005; 43:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/88\">",
"      Freebourn TM, Barber DB, Able AC. The treatment of immature heterotopic ossification in spinal cord injury with combination surgery, radiation therapy and NSAID. Spinal Cord 1999; 37:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/89\">",
"      Teasell RW, Mehta S, Aubut JL, et al. A systematic review of the therapeutic interventions for heterotopic ossification after spinal cord injury. Spinal Cord 2010; 48:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/90\">",
"      Banovac K, Williams JM, Patrick LD, Haniff YM. Prevention of heterotopic ossification after spinal cord injury with indomethacin. Spinal Cord 2001; 39:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/91\">",
"      Banovac K, Williams JM, Patrick LD, Levi A. Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). Spinal Cord 2004; 42:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/92\">",
"      Banovac K, Gonzalez F, Renfree KJ. Treatment of heterotopic ossification after spinal cord injury. J Spinal Cord Med 1997; 20:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/93\">",
"      Banovac K, Gonzalez F, Wade N, Bowker JJ. Intravenous disodium etidronate therapy in spinal cord injury patients with heterotopic ossification. Paraplegia 1993; 31:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/94\">",
"      Banovac K. The effect of etidronate on late development of heterotopic ossification after spinal cord injury. J Spinal Cord Med 2000; 23:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/95\">",
"      Sautter-Bihl ML, H&uuml;ltenschmidt B, Liebermeister E, Nanassy A. Fractionated and single-dose radiotherapy for heterotopic bone formation in patients with spinal cord injury. A phase-I/II study. Strahlenther Onkol 2001; 177:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/96\">",
"      Stover SL, Niemann KM, Tulloss JR. Experience with surgical resection of heterotopic bone in spinal cord injury patients. Clin Orthop Relat Res 1991; :71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/97\">",
"      McAuliffe JA, Wolfson AH. Early excision of heterotopic ossification about the elbow followed by radiation therapy. J Bone Joint Surg Am 1997; 79:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/98\">",
"      Sautter-Bihl ML, Liebermeister E, Nanassy A. Radiotherapy as a local treatment option for heterotopic ossifications in patients with spinal cord injury. Spinal Cord 2000; 38:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/99\">",
"      Dalyan M, Sherman A, Cardenas DD. Factors associated with contractures in acute spinal cord injury. Spinal Cord 1998; 36:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/100\">",
"      Harvey LA, Herbert RD. Muscle stretching for treatment and prevention of contracture in people with spinal cord injury. Spinal Cord 2002; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/101\">",
"      Gellman H, Sie I, Waters RL. Late complications of the weight-bearing upper extremity in the paraplegic patient. Clin Orthop Relat Res 1988; :132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/102\">",
"      Hastings J, Goldstein B. Paraplegia and the shoulder. Phys Med Rehabil Clin N Am 2004; 15:vii, 699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/103\">",
"      Sinnott KA, Milburn P, McNaughton H. Factors associated with thoracic spinal cord injury, lesion level and rotator cuff disorders. Spinal Cord 2000; 38:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/104\">",
"      Paralyzed Veterans of America Consortium for Spinal Cord Medicine. Preservation of upper limb function following spinal cord injury: a clinical practice guideline for health-care professionals. J Spinal Cord Med 2005; 28:434.",
"     </a>",
"    </li>",
"    <li>",
"     Yarkony, GM, Heinemann, AW. Pressure ulcers. In: Spinal cord injury: Clinical outcomes from the model systems, Stover, SL, DeLisa, JA, Whiteneck, GG, (Eds), Aspen Publishing, Gaithersburg, MD 1995. p.100.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/106\">",
"      Satkunam LE. Rehabilitation medicine: 3. Management of adult spasticity. CMAJ 2003; 169:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/107\">",
"      Adams MM, Hicks AL. Spasticity after spinal cord injury. Spinal Cord 2005; 43:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/108\">",
"      Taricco M, Adone R, Pagliacci C, Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev 2000; :CD001131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/109\">",
"      Burke D, Gillies JD, Lance JW. An objective assessment of a gamma aminobutyric acid derivative in the control of spasticity. Proc Aust Assoc Neurol 1971; 8:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/110\">",
"      Burchiel KJ, Hsu FP. Pain and spasticity after spinal cord injury: mechanisms and treatment. Spine (Phila Pa 1976) 2001; 26:S146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/111\">",
"      Nance PW. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. J Am Paraplegia Soc 1994; 17:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/112\">",
"      Simpson DM, Gracies JM, Yablon SA, et al. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry 2009; 80:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/113\">",
"      Corbett M, Frankel HL, Michaelis L. A double blind, cross-over trial of Valium in the treatment of spasticity. Paraplegia 1972; 10:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/114\">",
"      Gruenthal M, Mueller M, Olson WL, et al. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord 1997; 35:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/115\">",
"      Stewart JE, Barbeau H, Gauthier S. Modulation of locomotor patterns and spasticity with clonidine in spinal cord injured patients. Can J Neurol Sci 1991; 18:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/116\">",
"      Norman KE, P&eacute;pin A, Barbeau H. Effects of drugs on walking after spinal cord injury. Spinal Cord 1998; 36:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/117\">",
"      Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/118\">",
"      Hugenholtz H, Nelson RF, Dehoux E, Bickerton R. Intrathecal baclofen for intractable spinal spasticity--a double-blind cross-over comparison with placebo in 6 patients. Can J Neurol Sci 1992; 19:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/119\">",
"      McClelland S 3rd, Bethoux FA, Boulis NM, et al. Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. Muscle Nerve 2008; 37:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/120\">",
"      Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1691.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Information for healthcare professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc). Available at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm (Accessed on August 5, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/122\">",
"      Siddall PJ, Loeser JD. Pain following spinal cord injury. Spinal Cord 2001; 39:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/123\">",
"      Wasner G, Lee BB, Engel S, McLachlan E. Residual spinothalamic tract pathways predict development of central pain after spinal cord injury. Brain 2008; 131:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/124\">",
"      Drewes AM, Andreasen A, Poulsen LH. Valproate for treatment of chronic central pain after spinal cord injury. A double-blind cross-over study. Paraplegia 1994; 32:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/125\">",
"      Finnerup NB, Sindrup SH, Bach FW, et al. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 2002; 96:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/126\">",
"      Tai Q, Kirshblum S, Chen B, et al. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med 2002; 25:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/127\">",
"      Finnerup NB, Jensen TS. Spinal cord injury pain--mechanisms and treatment. Eur J Neurol 2004; 11:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/128\">",
"      Siddall PJ, Cousins MJ, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006; 67:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/129\">",
"      Davidoff G, Guarracini M, Roth E, et al. Trazodone hydrochloride in the treatment of dysesthetic pain in traumatic myelopathy: a randomized, double-blind, placebo-controlled study. Pain 1987; 29:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/130\">",
"      Cardenas DD, Warms CA, Turner JA, et al. Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain 2002; 96:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/131\">",
"      Cardenas DD, Jensen MP. Treatments for chronic pain in persons with spinal cord injury: A survey study. J Spinal Cord Med 2006; 29:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/132\">",
"      Siddall PJ, Molloy AR, Walker S, et al. The efficacy of intrathecal morphine and clonidine in the treatment of pain after spinal cord injury. Anesth Analg 2000; 91:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/133\">",
"      Herman RM, D'Luzansky SC, Ippolito R. Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. Clin J Pain 1992; 8:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/134\">",
"      Denkers MR, Biagi HL, Ann O'Brien M, et al. Dorsal root entry zone lesioning used to treat central neuropathic pain in patients with traumatic spinal cord injury: a systematic review. Spine (Phila Pa 1976) 2002; 27:E177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/135\">",
"      Lee TT, Alameda GJ, Camilo E, Green BA. Surgical treatment of post-traumatic myelopathy associated with syringomyelia. Spine (Phila Pa 1976) 2001; 26:S119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/136\">",
"      Brodbelt AR, Stoodley MA. Post-traumatic syringomyelia: a review. J Clin Neurosci 2003; 10:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/137\">",
"      Schurch B, Wichmann W, Rossier AB. Post-traumatic syringomyelia (cystic myelopathy): a prospective study of 449 patients with spinal cord injury. J Neurol Neurosurg Psychiatry 1996; 60:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/138\">",
"      Abel R, Gerner HJ, Smit C, Meiners T. Residual deformity of the spinal canal in patients with traumatic paraplegia and secondary changes of the spinal cord. Spinal Cord 1999; 37:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/139\">",
"      Vannemreddy SS, Rowed DW, Bharatwal N. Posttraumatic syringomyelia: predisposing factors. Br J Neurosurg 2002; 16:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/140\">",
"      Perrouin-Verbe B, Lenne-Aurier K, Robert R, et al. Post-traumatic syringomyelia and post-traumatic spinal canal stenosis: a direct relationship: review of 75 patients with a spinal cord injury. Spinal Cord 1998; 36:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/141\">",
"      Holly LT, Johnson JP, Masciopinto JE, Batzdorf U. Treatment of posttraumatic syringomyelia with extradural decompressive surgery. Neurosurg Focus 2000; 8:E8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/142\">",
"      Sgouros S, Williams B. Management and outcome of posttraumatic syringomyelia. J Neurosurg 1996; 85:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/143\">",
"      Batzdorf U, Klekamp J, Johnson JP. A critical appraisal of syrinx cavity shunting procedures. J Neurosurg 1998; 89:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/144\">",
"      Kramer KM, Levine AM. Posttraumatic syringomyelia: a review of 21 cases. Clin Orthop Relat Res 1997; :190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/145\">",
"      Carroll AM, Brackenridge P. Post-traumatic syringomyelia: a review of the cases presenting in a regional spinal injuries unit in the north east of England over a 5-year period. Spine (Phila Pa 1976) 2005; 30:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/146\">",
"      Lee TT, Alameda GJ, Gromelski EB, Green BA. Outcome after surgical treatment of progressive posttraumatic cystic myelopathy. J Neurosurg 2000; 92:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/147\">",
"      North NT. The psychological effects of spinal cord injury: a review. Spinal Cord 1999; 37:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/148\">",
"      DeVivo MJ, Black KJ, Richards JS, Stover SL. Suicide following spinal cord injury. Paraplegia 1991; 29:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/149\">",
"      Kaplin AI, Krishnan C, Deshpande DM, et al. Diagnosis and management of acute myelopathies. Neurologist 2005; 11:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/150\">",
"      Krassioukov AV, Karlsson AK, Wecht JM, et al. Assessment of autonomic dysfunction following spinal cord injury: rationale for additions to International Standards for Neurological Assessment. J Rehabil Res Dev 2007; 44:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/151\">",
"      Yarkony GM, Roth EJ, Heinemann AW, Lovell LL. Spinal cord injury rehabilitation outcome: the impact of age. J Clin Epidemiol 1988; 41:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/48/37642/abstract/152\">",
"      Kirshblum S. New rehabilitation interventions in spinal cord injury. J Spinal Cord Med 2004; 27:342.",
"     </a>",
"    </li>",
"    <li>",
"     Braddom R. Physical medicine and rehabilitation, 2nd, WB Saunders Company, Philadelphia 2000. p.1236.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4839 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37642=[""].join("\n");
var outline_f36_48_37642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10148218\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIFE EXPECTANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CARDIOVASCULAR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Autonomic dysreflexia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PULMONARY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      URINARY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bladder dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Urinary calculi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SEXUAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GASTROINTESTINAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      BONE METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Heterotopic ossification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MUSCULOSKELETAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PRESSURE ULCERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SPASTICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Oral medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Intrathecal baclofen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Injection techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PAIN SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      NEUROLOGIC DETERIORATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Syringomyelia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Progressive posttraumatic myelomalacic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PSYCHIATRIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      THERMOREGULATORY DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      FUNCTIONAL DEFICITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4839\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4839|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/56/40843\" title=\"table 1\">",
"      Medications for spasticity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/53/43868\" title=\"table 2\">",
"      Functional recovery after SCI by level",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=related_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15479?source=related_link\">",
"      Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5832?source=related_link\">",
"      Anatomy and localization of spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/39/1658?source=related_link\">",
"      Complications of total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=related_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20634?source=related_link\">",
"      Neurologic disorders complicating pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30695?source=related_link\">",
"      Options in the management of renal and ureteral stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/3/35896?source=related_link\">",
"      Overview of joint protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/0/16386?source=related_link\">",
"      Patient information: Neurogenic bladder in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/53/27475?source=related_link\">",
"      Patient information: Paraplegia and quadriplegia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1049?source=related_link\">",
"      Prevention of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5514?source=related_link\">",
"      Recurrent urinary tract infection in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/28/42439?source=related_link\">",
"      Respiratory complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23321?source=related_link\">",
"      Respiratory physiologic changes following spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37799?source=related_link\">",
"      Superior mesenteric artery syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/61/6105?source=related_link\">",
"      Treatment of hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5161?source=related_link\">",
"      Treatment of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37064?source=related_link\">",
"      Treatment of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19336?source=related_link\">",
"      Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_48_37643="Vaginal estrogen";
var content_f36_48_37643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Vaginal estrogen preparations available in the United States for treatment of vaginal atrophy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Preparation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Available strengths",
"       </td>",
"       <td class=\"subtitle1\">",
"        Regimen",
"        <br/>",
"        (recommended by manufacturer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Vaginal ring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Estring&reg;",
"       </td>",
"       <td>",
"        7.5 mcg estradiol/day, released over 90 days",
"       </td>",
"       <td>",
"        Ring is inserted into the vaginal by the patient or clinician. Ring is removed and replaced with a new ring every 90 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Vaginal tablet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vagifem&reg;",
"       </td>",
"       <td>",
"        10 mcg estradiol/tablet",
"       </td>",
"       <td>",
"        Insert 1 tablet intravaginally daily for 2 weeks, followed by twice weekly.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Vaginal cream",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Premarin&reg;",
"       </td>",
"       <td>",
"        0.625 mg conjugated estrogens/g of cream",
"       </td>",
"       <td>",
"        0.5 g of cream intravaginally administered twice weekly. Cyclic regimen also listed in instructions for use, but not commonly used.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Estrace&reg;",
"       </td>",
"       <td>",
"        100 mcg estradiol/g of cream",
"       </td>",
"       <td>",
"        2 to 4 g of cream intravaginally administered daily for one or 1 or 2 weeks, then gradually reduce to half the initial dosage for a similar period. A maintenance dosage of 1 g of cream, 1 to 3 times per week may be used.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37643=[""].join("\n");
var outline_f36_48_37643=null;
var title_f36_48_37644="Gold vs auranofin in RA II";
var content_f36_48_37644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F73096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F73096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of GSTM and auranofin in patients with rheumatoid arthritis*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        0",
"       </td>",
"       <td class=\"subtitle1\">",
"        3",
"       </td>",
"       <td class=\"subtitle1\">",
"        6",
"       </td>",
"       <td class=\"subtitle1\">",
"        9",
"       </td>",
"       <td class=\"subtitle1\">",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"2\">",
"        Continuing study",
"       </td>",
"       <td>",
"        GSTM",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AF",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Withdrawn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Adverse reaction",
"       </td>",
"       <td>",
"        GSTM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AF",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Lack of effect",
"       </td>",
"       <td>",
"        GSTM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AF",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"2\">",
"        Miscellaneous",
"       </td>",
"       <td>",
"        GSTM",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AF",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Comparison of the effects of gold sodium thiomalate (GSTM) and auranofin (AF) in 120 patients with rheumatoid arthritis who were treated for one year. Numbers of patients continuing on drug and cumulative withdrawals with respect to adverse reaction, lack of effect, and miscellaneous reasons at months 3, 6, 9, and 12 are shown. Some patients withdrew for more than one reason. More patients in the auranofin group dropped out because of lack of effect, while more patients dropped out in the GSTM group due to drug toxicity.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Davis, P, Menard, H, Thompson, J, et al, J Rheumatol 1985; 12:60.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37644=[""].join("\n");
var outline_f36_48_37644=null;
var title_f36_48_37645="PD cath exit site appearance";
var content_f36_48_37645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F61012%7ENEPH%2F73832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F61012%7ENEPH%2F73832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grading of peritoneal catheter exit site based upon appearance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perfect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Good",
"       </td>",
"       <td class=\"subtitle1\">",
"        Equivocal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acute infection &lt;4 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chronic infection &gt;4",
"weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cuff infection without exit",
"infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain/tenderness",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        Only if exacerbation",
"       </td>",
"       <td>",
"        May be present over cuff",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Color",
"       </td>",
"       <td>",
"        Natural, pale pink or dark",
"       </td>",
"       <td>",
"        Natural, pale pink, purplish or dark, bright pink",
"&lt;13 mm",
"       </td>",
"       <td>",
"        Bright pink or red &lt;13 mm",
"       </td>",
"       <td>",
"        Bright pink or red &gt;13 mm",
"       </td>",
"       <td>",
"        Bright pink or red &gt;13 mm only if exacerbation",
"       </td>",
"       <td>",
"        Natural, pale pink, purplish or dark, bright pink",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crust",
"       </td>",
"       <td>",
"        None or small, easily detached or specks of crust on",
"dressing",
"       </td>",
"       <td>",
"        None or small, easily detached or specks of crust on",
"dressing",
"       </td>",
"       <td>",
"        Present, may be large and difficult to detach",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Present, may be difficult to detach",
"       </td>",
"       <td>",
"        Typically absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scab",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Drainage",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        None",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        None",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        None even with pressure on sinus; dried exudate on",
"dressing",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Purulent or bloody, spontaneous or after pressure on",
"sinus; wet exudate on dressing",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Purulent or bloody, wet exudate on dressing",
"       </td>",
"       <td>",
"        Chronic or intermittent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Purulent, bloody, tenacious or 'gluey'",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Swelling",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        Occurs only if exacerbation",
"       </td>",
"       <td>",
"        Cuff induration may be felt on palpation; negative",
"ultrasound does not rule out the diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulation",
"tissue",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Plain or slightly exuberant",
"       </td>",
"       <td>",
"        Slightly exuberant or 'proud flesh' may be present",
"       </td>",
"       <td>",
"        'Proud flesh' or slightly exuberant typically visible",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Trauma may result in pain, bleeding, scab, and deterioration of exit apearance. Exit appearance depends on intensity of trauma and time of evaluation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Twardowski, ZJ, Prowant, BF. Nephrol Dial Transplant 1997; 12:1284. Copyright &copy; 1997 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grading of pertioneal catheter sinus tract based upon exit site appearance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perfect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Good",
"       </td>",
"       <td class=\"subtitle1\">",
"        Equivocal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acute infection &lt;4 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chronic infection &gt;4 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cuff infection without exit infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epithelium",
"       </td>",
"       <td>",
"        Strong, mature. Covers visible sinus",
"       </td>",
"       <td>",
"        Strong, mature at rim. Fragile or mucosal deeper",
"       </td>",
"       <td>",
"        Absent or covers part of sinus",
"       </td>",
"       <td>",
"        Absent or covers only part of sinus",
"       </td>",
"       <td>",
"        Absent or covers only part of sinus",
"       </td>",
"       <td>",
"        Covers most or all of sinus. May be macerated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulation tissue",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Plain beyond epithelium",
"       </td>",
"       <td>",
"        Slightly exuberant",
"       </td>",
"       <td>",
"        Slightly exuberant or 'proud flesh'",
"       </td>",
"       <td>",
"        'Proud flesh' or slightly exuberant",
"       </td>",
"       <td>",
"        None or exuberant deep in sinus.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Drainage",
"       </td>",
"       <td>",
"        None or barely visible",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        None or barely visible",
"       </td>",
"       <td>",
"        Purulent or bloody.",
"       </td>",
"       <td>",
"        Purulent or bloody",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Purulent or bloody",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Purulent, bloody, gluey. May be seen only after pressure on cuff. Clot or dreed blood in sinus.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clear or thick",
"       </td>",
"       <td>",
"        Clear or thick",
"       </td>",
"       <td>",
"        Sometimes clear",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Twardowski, ZJ, Prowant, BF. Nephrol Dial Transplant 1997; 12:1284. Copyright &copy; 1997 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37645=[""].join("\n");
var outline_f36_48_37645=null;
var title_f36_48_37646="Contents: Medical consultation";
var content_f36_48_37646=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Medical consultation",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Medical consultation",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Medical consultation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/1/4120\">",
"           Evaluation of health-related quality of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/41/21145\">",
"           Medical consultation for electroconvulsive therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/58/33706\">",
"           Medical consultation for patients with hip fracture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/48/41735\">",
"           Overview of the principles of medical consultation and perioperative medicine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/29/42456\">",
"           Surgical issues in HIV infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Perioperative care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/12/6344\">",
"           Elective noncardiac surgery after percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/50/35626\">",
"           Management of anticoagulation before and after elective surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/45/29402\">",
"           Management of cardiac risk for noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/47/36601\">",
"           Medical management of the dialysis patient undergoing surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/14/13544\">",
"           Noncardiac surgery in patients with aortic stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/11/13495\">",
"           Noncardiac surgery in patients with mitral or aortic regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/2/4137\">",
"           Nonthyroid surgery in the patient with thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/22/19817\">",
"           Overview of anesthesia and anesthetic choices",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/9/10394\">",
"           Perioperative care of the surgical patient with neurologic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/0/18440\">",
"           Perioperative heart failure in noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/63/29688\">",
"           Perioperative management of diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/17/33046\">",
"           Perioperative management of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/45/40666\">",
"           Perioperative medication management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/17/29975\">",
"           Perioperative myocardial infarction after noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/62/17384\">",
"           The surgical patient taking glucocorticoids",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Postoperative care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/28/39368\">",
"           Early cardiac complications of coronary artery bypass graft surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/25/35226\">",
"           Early noncardiac complications of coronary artery bypass graft surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/50/35626\">",
"           Management of anticoagulation before and after elective surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/47/36601\">",
"           Medical management of the dialysis patient undergoing surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/2/4137\">",
"           Nonthyroid surgery in the patient with thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/10/11434\">",
"           Overview of the management of postoperative pulmonary complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/17/29975\">",
"           Perioperative myocardial infarction after noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/32/6664\">",
"           Perioperative nutritional support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/40/38537\">",
"           Postoperative complications among patients undergoing cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/46/19178\">",
"           Postoperative fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/51/13113\">",
"           Strategies to reduce postoperative pulmonary complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/62/17384\">",
"           The surgical patient taking glucocorticoids",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Preoperative evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/35/12858\">",
"           Assessing surgical risk in patients with liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/27/40378\">",
"           Carotid endarterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/12/6344\">",
"           Elective noncardiac surgery after percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/60/36810\">",
"           Estimation of cardiac risk prior to noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/8/1162\">",
"           Evaluation of preoperative pulmonary risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/50/35626\">",
"           Management of anticoagulation before and after elective surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/45/29402\">",
"           Management of cardiac risk for noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/47/36601\">",
"           Medical management of the dialysis patient undergoing surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/14/13544\">",
"           Noncardiac surgery in patients with aortic stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/11/13495\">",
"           Noncardiac surgery in patients with mitral or aortic regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/2/4137\">",
"           Nonthyroid surgery in the patient with thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/55/39800\">",
"           Overview of preoperative evaluation and preparation for gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/32/6664\">",
"           Perioperative nutritional support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/43/32439\">",
"           Preoperative assessment of hemostasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/35/15929\">",
"           Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/2/15400\">",
"           Preoperative evaluation for lung resection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/40/24201\">",
"           Preoperative management of patients with cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/4/10314\">",
"           Preoperative medical evaluation of the healthy patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/62/17384\">",
"           The surgical patient taking glucocorticoids",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-7DEA4B072E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f36_48_37646=[""].join("\n");
var outline_f36_48_37646=null;
var title_f36_48_37647="Tarsal tunnel anatomy";
var content_f36_48_37647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tarsal tunnel anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tarsal tunnel syndrome is caused by entrapment of the posterior tibial nerve beneath the flexor retinaculum on the medial side of the ankle. Entrapment may also include the two branches, the medial and lateral plantar nerves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_48_37647=[""].join("\n");
var outline_f36_48_37647=null;
